Washington University in St. Louis

Washington University Open Scholarship
All Theses and Dissertations (ETDs)
1-1-2012

Modulation of Ly49A+ Natural Killer Cell Licensing by Major
Histocompatibility Complex Class I Alleles
Anna Jonsson
Washington University in St. Louis

Follow this and additional works at: https://openscholarship.wustl.edu/etd

Recommended Citation
Jonsson, Anna, "Modulation of Ly49A+ Natural Killer Cell Licensing by Major Histocompatibility Complex
Class I Alleles" (2012). All Theses and Dissertations (ETDs). 595.
https://openscholarship.wustl.edu/etd/595

This Dissertation is brought to you for free and open access by Washington University Open Scholarship. It has
been accepted for inclusion in All Theses and Dissertations (ETDs) by an authorized administrator of Washington
University Open Scholarship. For more information, please contact digital@wumail.wustl.edu.

WASHINGTON UNIVERSITY IN ST. LOUIS
Division of Biology and Biomedical Sciences
Immunology

Dissertation Examination Committee:
Wayne M. Yokoyama, Chair
Marco Colonna
Todd Fehniger
Ted Hansen
Chyi-Song Hsieh
Emil Unanue

Modulation of Ly49A+ Natural Killer Cell Licensing by
Major Histocompatibility Complex Class I Alleles
by
Anna Helena Jonsson

A dissertation presented to the
Graduate School of Arts and Sciences
of Washington University in
partial fulfillment of the
requirements for the degree
of Doctor of Philosophy

May 2012
St. Louis, Missouri
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Natural killer (NK) cells are innate immune lymphocytes that react to cells
lacking self-MHC (major histocompatibility complex) class I molecules, such as
transformed or virally infected host cells and allogeneic bone marrow. This reactivity is
mediated by inhibitory receptors for MHC class I that block the ability of activation
receptors to stimulate NK cells. Since many NK cells lack receptors that recognize selfMHC, the inhibitory receptors also mediate a second function, termed NK cell licensing,
to protect against autoreactivity. To become licensed, i.e. functionally competent to be
triggered through its activation receptors, an NK cell must engage host MHC class I via
at least one of its MHC class I-specific inhibitory receptors, which in mice belong to the
Ly49 family of receptors. However, many properties of this process remain unclear.
To explore potential determinants of NK cell licensing on a single Ly49 receptor,
we have investigated the relative licensing impacts of the b, d, k, q, r, and s H2
haplotypes on Ly49A+ NK cells. In ex vivo stimulation assays, some Ly49A-MHC class
I haplotype combinations produced an intermediate licensing phenotype, indicating that
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licensing is not a binary phenomenon. Comparisons of these data with soluble Ly49A
tetramer binding assays indicate that licensing is essentially analog but is saturated by
moderate-binding MHC class I ligands. Interestingly, licensing exhibited a strong inverse
correlation with Ly49A surface accessibility, a measure of cis engagement of Ly49A
with MHC class I expressed on the same cell. Finally, Ly49A-mediated effector
inhibition was found to be more sensitive to MHC class I engagement than licensing of
Ly49A+ NK cells, suggesting that licensing establishes a margin of safety against NK cell
autoreactivity.
We have also developed a transgenic mouse model with inducible MHC class I
expression for use in future studies of NK cell licensing. Upon administration of
doxycycline, these mice express a H2Kb-!2m-ova peptide single-chain MHC class I
trimer, which will license Ly49C+ NK cells. Preliminary data suggest that this model of
inducible NK cell licensing will be useful for studies of the kinetics of NK cell licensing
both in vivo and in vitro.
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CHAPTER 1

INTRODUCTION
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Natural killer (NK) cells are innate immune lymphocytes that produce proinflammatory cytokines and kill transformed and virally infected cells. Unlike B and T
lymphocytes, which use unique somatically rearranged antigen-specific receptors, e.g.,
the B or T cell receptor, NK cells rely on germline-encoded receptors belonging to
several families that often include both activating and inhibitory members. During
effector responses, NK cells detect alterations in endogenous protein expression on target
cells by integrating signals from a number of these germ line-encoded activation and
inhibitory receptors (1, 2). The balance of signals mediated by these receptors determines
the NK cell response to the target. In certain disease states, such as cancers and viral
infections, the inhibitory signal is decreased or absent, allowing the activation signal to
dominate and trigger cytokine production and/or cytotoxic effector mechanisms.
Pathological conditions can also induce expression of activating ligands on a target cell
that lead to NK cell activation by overpowering inhibitory signals.

Activating and inhibitory NK cell receptors
Activating and inhibitory NK cell receptors belong to the same family of proteins.
In humans, the predominant NK cell receptors are the killer-cell immunoglobulin (Ig)like receptors (KIRs), type I integral membrane proteins that form a polymorphic family
within the immunoglobulin superfamily (3, 4). In mice, the major NK cell receptors are
type II integral membrane, C-type lectin-like molecules belonging to the Ly49 family (5,
6). Both human and mouse NK cells also express a conserved lectin-like heterodimeric
receptor, CD94 coupled with members of the NKG2 family. The lectin-like homodimer
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NKG2D is an activation receptor expressed by both human and murine NK cells that
binds stress-induced ligands with MHC class I-like structures (7, 8).
Most MHC-specific inhibitory NK cell receptors recognize MHC class Ia
molecules or, in the case of NKG2/CD94, the MHC class Ib molecule Qa-1 (in humans,
HLA-E), which presents signal peptides from MHC class Ia molecules and thereby
provides an indirect measure of MHC class Ia expression (5, 9). Ligands of MHCspecific inhibitory receptors tend to be constitutively expressed on healthy cells but are
often downregulated in instances of viral infection or cellular transformation (10-12).
Notably, several viruses have developed decoy MHC class I-like receptors in an attempt
to avoid NK cell activation, an evolutionary indication of the importance of the antiviral
activities of NK cells (13). The inhibitory receptors of the KIR and Ly49 families have an
immunoreceptor tyrosine-based inhibitory motif (ITIM) in their cytoplasmic tails that
predominantly associates with the cytoplasmic tyrosine phosphatase, SHP-1, though the
ITIM may potentially recruit other signaling molecules (5, 14, 15).
The activating KIRs and Ly49 receptors are structurally related to their inhibitory
counterparts but lack cytoplasmic ITIMs. Instead, they have short cytoplasmic tails and
associate via charged transmembrane residues with DAP12 or other immunoreceptor
tyrosine-based activation motif (ITAM)-containing signaling chains for normal
expression and signal transduction (5, 16). Activating receptors outside the KIR and Ly49
families also use separate signaling chains. Ligands of activation receptors include both
MHC class I-like molecules and unrelated proteins, though the ligands of many activation
receptors remain undetermined. Some activating receptors, like Ly49H, bind to virally
encoded ligands (17, 18). Others, like NKG2D, bind host ligands that are constitutively
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expressed at low levels on healthy cells and are upregulated in response to cellular stress
and other stimuli (8, 19). The upregulation of such ligands is termed “induced-self” and
enhances activation of NK cells by diseased cells.

The “missing self” theory of NK cell function
NK cells were first identified by their ability to kill tumor cells “naturally,” i.e.,
without prior exposure (20). This ability distinguished them from T cells, which require
previous exposure to the tumor cells in order to efficiently kill them. Since NK cells do
not have unique antigen-specific receptors like T cells, it was long a mystery how they
identified the tumor as an appropriate target cell. The answer was provided by Klas Kärre
and colleagues, who discovered that NK cells preferentially kill target cells that lack
MHC class I expression (21). This led to the proposal of the “missing self” theory of NK
cell function, which states that NK cells scan host cells for proper expression of MHC
class I. Host cells that have downregulated MHC class I, for example as a result of viral
infection are thus identified and eliminated by NK cells. In this way, NK cells have a role
that is complementary to CD8 T cells, which respond to MHC class I bound to foreign
peptides. As virally infected or transformed cells try to evade CD8 T cell attack by downregulating MHC class I, they become susceptible to NK cell attack instead. The
subsequent identification of MHC class I-specific inhibitory Ly49 receptors and KIRs
provided a molecular basis for missing-self reactivity and tolerance to normal MHCexpressing cells (22-24).
However, there were two problems with the missing-self theory of NK cell
function. The first problem was the lack of NK cell auto-aggression in MHC class I-
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deficient mice. According to the missing-self hypothesis, NK cells in MHC class Ideficient hosts should attack self cells because they are unable to engage MHC class I via
any inhibitory receptor. However, data from both !2m-/- mice and TAP1-/- mice
demonstrate that NK cells in these mice are actually hyporesponsive (25, 26). In these
mice, there is little or no engagement of any self-specific inhibitory receptor, yet the
!2m-/- NK cells remain inert to healthy self cells. Furthermore, NK cells from MHC class
I-deficient mice are poor responders to plate-bound anti-activation receptor antibody
cross-linking, which is entirely independent of engagement of the inhibitory Ly49
receptors or other as-yet undefined receptors that may be involved in target recognition
(27). These findings suggested that a different mechanism of NK cell tolerance governs
these NK cells.
The second problem with the missing-self hypothesis concerns the necessity of
pairing inhibitory NK receptors with their cognate MHC class I ligands. Ly49 receptors
and KIRs, as well as their MHC ligands, are highly polymorphic. In addition, each
inhibitory receptor binds only a subset of MHC class I alleles, and the Ly49 and KIR loci
are not genetically linked to the MHC locus. The Ly49s are encoded in the NK gene
complex (NKC) on distal mouse chromosome 6 whereas the KIRs are encoded in the
leukocyte receptor complex (LRC) on human chromosome 19q13.4 (16, 28). In contrast,
the MHC region is on mouse chromosome 17 and human chromosome 6p21,
respectively. In other words, the genes for the NK cell receptors and MHC ligands
segregate independently.
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Early models of NK cell self-tolerance
Several models were created to address the gaps in the missing-self theory of NK
cell function. One early model proposed that all NK cells express at least one receptor
specific for self-MHC, thus ensuring self-tolerance of all NK cells in MHC class Isufficient hosts. This model was initially based on the finding that NK cell clones
established from two normal human donors all appeared to express at least one selfspecific inhibitory receptor (29). Several studies in mice also appeared to support this
hypothesis. First, expression of Ly49 and KIR alleles during development is sequential
and, once established, appears to be fixed for each NK cell (2, 30). Second, the host
MHC haplotype affects the frequency of cells expressing a given Ly49. For example,
mice that express an MHC class I ligand for Ly49A (e.g. H2Dd) have a lower frequency
of Ly49A+ NK cells than MHC-congenic mice that lack a ligand for Ly49A (e.g. H2b) or
MHC-deficient mice (31, 32). Together, these data suggested that NK cells accumulate
additional inhibitory receptors until they are able to engage self-MHC and are consistent
with the “at least one” hypothesis.
More recent work, however, has shown that a significant fraction of the NK cell
population of both mice and humans lacks any known receptor for self-MHC (27, 33,
34). Like NK cells from MHC class I-deficient mice, these “self-blind” cells are
hyporesponsive in that they do not kill MHC class I-deficient targets as well as NK cells
expressing self-MHC-specific inhibitory receptors. It cannot be formally excluded that
these cells express as-yet unidentified inhibitory receptor(s) for self, and the cause of
their deficiency in target killing could be related to expression (or lack thereof) of
undefined target cell ligands for either inhibitory or activation receptors. However, these
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findings suggested that a tolerance mechanism separate from self-MHC engagement by
inhibitory NK receptors might be at work.
Another model for tolerance, the receptor calibration model, focused on
differences in Ly49 expression levels on individual NK cells from mice with different
MHC haplotypes (35-37). Ly49 surface staining is significantly lower on NK cells from
hosts with self-MHC that can bind the given Ly49 than on NK cells from mice that lack
self-MHC. For example, Ly49A+ NK cells from mice expressing self-MHC (e.g. H2Dd)
have lower levels of surface Ly49A than Ly49A+ NK cells from mice lacking self-MHC
(e.g. H2b or !2m-/-) (31, 35, 38). Recent studies in humans indicate a similar trend of
decreased surface inhibitory KIR levels in individuals who express the cognate human
leukocyte antigen (HLA) ligand (39). Thus, expression levels of NK cell receptors for
MHC are altered in hosts with the cognate MHC ligand.
According to the postulated kinetics of receptor engagement and signaling in the
receptor calibration model, an NK cell with a lower level of expression of an inhibitory
receptor would require a higher level of ligand expression in order to achieve engagement
sufficient to reach the threshold for inhibitory signaling (37). This was the proposed
explanation for the finding that Ly49Alow NK cells had a higher threshold for inhibition
by H2Dd than Ly49Ahi NK cells (40). In mice, the Ly49Alow NK cells were better able to
kill tumor targets expressing reduced H2Dd than Ly49Ahigh NK cells isolated from a
mouse lacking self-MHC, which were completely inhibited (41). Interestingly, in an H2b
MHC class I mosaic mouse, where MHC class I is expressed on some cells but not
others, Ly49C levels were reduced on both MHC-deficient and MHC-sufficient NK cells
(42). Culture in interleukin (IL)-2 for four days restored normal (i.e. elevated) Ly49C
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surface expression on MHC-deficient cells, indicating that the surface expression level is
reversible depending on environmental conditions.
Recent findings propose a new interpretation for the data used to support the
receptor calibration model: the MHC-dependent reduction in apparent surface expression
of Ly49 receptors on NK cells can be explained by cis interactions between Ly49 and
MHC class I molecules expressed on the same NK cell (discussed further below) (43,
44). The amount of accessible surface Ly49 is lower on NK cells that co-express selfMHC, giving the appearance of reduced protein levels. In light of the new data on cis
engagements, the “receptor calibration” model might thus be better termed the “receptor
sequestration” model, where cis binding, instead of an actual decrease in expression,
modulates sensitivity to inhibition by self-MHC (44). Regardless, the receptor calibration
model still fails to explain why MHC class I-deficient NK cells respond so poorly to
MHC class I-deficient target cells and to plate-bound antibody stimulation, both of which
elicit robust responses by wild-type NK cells (26, 27). Thus, these older models of NK
cell tolerance do not account for observed NK cell functions, particularly in MHCdeficient hosts.

NK cell licensing
In 2005, the Yokoyama lab proposed a new theory, called NK cell licensing, for
NK cell tolerance in MHC class I-deficient hosts. NK cell licensing dictates that an NK
cell must to engage self-MHC class I in order to be responsive to subsequent stimuli
received via its activation receptors, a state termed “licensed” (Figure 1) (27, 45, 46). NK
cells that fail to engage self-MHC are unlicensed. Licensing occurs via the MHC class I-
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specific Ly49 receptors that were first identified as inhibitory receptors in effector
responses, and it requires the ITIM signaling motif (27). NK cell licensing ultimately
produces two types of self-tolerant NK cells with regard to self-MHC. Licensed NK cells
maintain self-tolerance by direct inhibition via self-MHC class I engagement through the
same receptor that conferred licensing. Unlicensed NK cells, which cannot engage selfMHC, are tolerant because they are highly resistant to stimulation received through their
activation receptors. Missing-self stimuli (e.g. Concanavalin (ConA)-treated !2m-/- blasts)
are not enough to activate unlicensed cells, whereas licensed cells respond robustly to
missing-self stimuli.
The licensing model arose from studies examining the responses of freshly
isolated NK cells upon target cell-free antibody cross-linking. Prior studies of NK cell
tolerance predominantly examined cultured NK cell killing of target cells, a strategy that
was useful in dissecting NK cell receptor specificity (22), but that could be problematic if
culture conditions affected functional attributes of otherwise naïve NK cells.
Furthermore, despite major advances, the entire repertoire of NK cell receptors and
ligands involved in target recognition is incompletely understood. To minimize these
potential confounding effects, Kim et al used freshly explanted, naïve NK cells that were
stimulated with plate-bound antibodies against NK cell activation receptors such as
NK1.1 (Nkrp1c), which is expressed on all immature and mature NK cells in C57BL/6
(H2b) mice. They then stained for intracellular interferon " (IFN") as an index of NK cell
activation, which, in conjunction with surface staining for lineage markers and Ly49
receptors, allowed for the functional characterization of individual NK cells.
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These studies revealed that only NK cells expressing an inhibitory receptor
specific for self-MHC class I produced IFN" upon ex vivo plate-bound antibody
stimulation (27). For example, Ly49A+ NK cells from MHC-congenic or transgenic (tg)
mice expressing H2Dd, a known ligand for Ly49A, produced abundant IFN" upon
stimulation. Ly49A+ NK cells from mice lacking an MHC ligand for Ly49A, such as the
H2b haplotype, produced significantly less IFN". Importantly, IFN" production in
response to PMA and ionomycin stimulation was the same for both licensed and
unlicensed NK cells, demonstrating that unlicensed cells are equipped to produce IFN".
Moreover, these findings were recapitulated with antibodies to other NK cell activation
receptors, including those with different associated ITAM-containing signaling chains. In
addition, production of other cytokines showed similar patterns, and the responsiveness
of licensed NK cells was also extended to target killing. Interestingly, CD94/NKG2A
expression did not clearly correlate with the licensed phenotype. Taken together, these
findings strongly suggested that a receptor specific for self-MHC must be engaged in
order for the NK cell to become functionally competent for triggering through an
activation receptor, i.e., NK cells are licensed by engagement of self-MHC-specific
receptors.
The requirement of the Ly49-MHC interaction in producing functionally
competent cells was conclusively demonstrated using a mouse (produced by the Hansen
Lab, Washington University, St. Louis, MO) transgenic for a H2Kb-ovalbumin (ova)
peptide single chain MHC class I trimer (SCT) on an otherwise MHC class I-deficient
background (Kb-/- Db-/- !2m-/-) (27). The H2Kb-ova SCT is the only expressed MHC class
I molecule in these mice, and it is exclusively recognized by Ly49C, as indicated by
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SCT-tetramer staining of primary NK cells from !2m-deficient mice (27). SCT-tetramer
staining was completely blocked by pre-incubation with an antibody monospecific for
Ly49C, establishing that the SCT is only recognized by Ly49C. As predicted by the
licensing model, Ly49C+ NK cells from these mice produced IFN" upon plate-bound
anti-NK1.1 stimulation, but NK cells lacking Ly49C expression did not. Thus, a selfMHC-specific receptor is required for licensing, and individual NK cells are separately
licensed, depending on their expressed receptors.
That individual NK cells are licensed separately based upon their expressed
inhibitory receptors provides an explanation for hybrid resistance, a phenomenon that
contradicts the classic laws of tissue transplantation. It has long been observed that while
F1 hybrid mice can accept skin grafts from either inbred parental strain, a T celldependent process, they reject parental bone marrow (BM) transplants (47, 48). Recipient
NK cells are responsible for this BM rejection, and it is dependent on the MHC
environment of the recipient (49, 50). Due to the stochastic expression pattern of
inhibitory NK receptors, licensing predicts that some NK cells will be licensed only by
MHC class I molecules inherited from the mother, while MHC class I molecules
inherited from the father will license a different set of NK cells. Because of the codominant expression of MHC class I molecules, all cells of the F1 progeny express both
the maternal and paternal MHC molecules, thereby maintaining self-tolerance of the
licensed NK cells. However, if BM from one parent is infused into the F1 progeny, NK
cell licensed to the other parent will mediate rejection of those BM cells as “missing
self.” Licensing provides a satisfying explanation for how NK cells can determine if a
cell expresses the full complement of self-MHC molecules, as in hybrid resistance.
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Proposed molecular mechanisms of licensing
The mechanism by which engagement of the self-MHC-specific receptor leads to
licensing has not been identified. The question of how an “inhibitory” receptor can have
an apparently positive effect on NK cell function is especially intriguing. Experiments
have demonstrated that the ITIM of the inhibitory receptor is required, but SHP-1, the
phosphatase that mediates effector inhibition, does not appear to be involved (27, 51).
Two general models dominate current thought on the molecular mechanism of NK cell
licensing: 1) the “arming” or “stimulatory receptor” hypothesis; and 2) the “disarming”
or “inhibitory receptor” hypothesis (45, 52). While there are not yet any definitive data to
prove or disprove either mechanism, it is useful to review the models and analyze the
existing data.
The “arming” mechanism postulates that NK cell licensing is directly induced by
the interaction of an inhibitory NK receptor with MHC class I. In other words, signaling
from the inhibitory receptor itself induces licensing. The arming mechanism of licensing
has been quite controversial because it ostensibly requires an “inhibitory” receptor to
produce a “positive” effect. However, with recent discoveries of novel signaling events
downstream of ITIMs, including phosphorylation events typically associated with
activation receptors (53), this possibility may not be as far-fetched as originally thought.
Alternatively, a different signaling milieu may exist during NK cell education as opposed
to during effector responses, resulting in different outcomes after the same or similar
receptor engagement.
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The “disarming” model proposes that self-MHC-specific NK cell receptors
oppose constitutive activation signals to induce licensing. In other words, they act akin to
their role in inhibiting effector responses by counteracting the signal of a postulated
second receptor that presumably recognizes self and activates the NK cell. In the absence
of an inhibitory signal from the self-MHC-specific receptor, the unmitigated activation
signals would cause the NK cell to become (or remain) unlicensed. Implicit in the
disarming model is the engagement of a self-specific activation receptor. Interestingly, no
single activation receptor or signaling chain is required for licensing as mice deficient in
each of the signaling molecules, DAP10, DAP12, FcR#I", and CD3$, had intact licensing
(27). A redundant role for these activation receptors cannot be excluded, however, as the
studies only included single knockout mice for each of these proteins.
A recent study from our group tested the arming and disarming models of NK cell
function (54). This study used a transgenic C57BL/6 mouse that ubiquitously expresses
m157, the murine cytomegalovirus (MCMV)-encoded ligand for the Ly49H NK cell
activation receptor (17, 18). The m157 transgenic mice were more susceptible to MCMV
infection and were unable to reject m157-transgenic BM, suggesting defects in Ly49H+
NK cells (54). These defects could not be attributed to decreased Ly49H expression or
fraction of Ly49H+ NK cells. Interestingly, Ly49H+ NK cells from these m157 transgenic
(tg) mice were hyporesponsive to both Ly49H-dependent and Ly49H-independent stimuli
in vitro, indicating a generalized hyporesponsiveness to stimulation. Continuous Ly49Hm157 interaction was necessary for these functional defects, which were also observed by
the Lanier group using retroviral gene transduction of m157 into hematopoietic stem cells
for BM reconstitution (55). Notably, the functional defects also occurred when mature
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wild-type NK cells were adoptively transferred to m157 tg mice, suggesting mature NK
cells can acquire hyporesponsiveness (54). Thus, continuous engagement of an activation
receptor results in hyporesponsiveness.
Importantly, NK cell tolerance due to Ly49H-m157 interaction was similar in
Ly49H+ NK cells regardless of expression of Ly49C, an inhibitory receptor specific for a
self-MHC allele in C57BL/6 mice (27, 54). Thus, in this mouse model, NK cell licensing
could not override the hyporesponsiveness caused by the constitutive m157-Ly49H
activation signal. In other words, engagement of self-specific activation receptors in vivo
induces an NK cell tolerance effect that is not affected by self-MHC-specific inhibitory
receptors. These findings suggest that self-tolerance to constitutive expression of
activating receptors is independent from NK cell licensing.

When and where does NK cell licensing occur?
NK cell licensing dictates that there must be a physical interaction between
inhibitory NK receptors and MHC class I to produce a functional NK cell. The details of
when, where, and with the assistance of what (if any) accessory cell this occurs remain a
mystery. Several pieces of circumstantial evidence suggest that NK cell licensing might
take place during maturation in the BM, where complete NK cell development is
assumed to occur. First, inhibitory receptors are expressed relatively early in NK cell
development (56, 57), and their expression coincides with the acquisition of functional
capabilities (30, 58). Second, in ontogeny, these inhibitory receptors appear to be
acquired sequentially in an MHC-dependent manner, meaning that an NK cell that can
engage self-MHC is less likely to express additional inhibitory receptors than an NK cell
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that cannot (yet) engage self-MHC (2, 30-32, 59). Finally, in vivo studies demonstrate
that BM NK cells undergo proliferation before reaching full developmental maturity (56).
NK cells that have self-MHC-specific receptors proliferate at a higher rate than NK cells
that lacking such receptors (27). Nonetheless, there is no direct evidence that NK cell
licensing must occur during development or in the environment of the bone marrow.
Is there a particular cell that must display MHC class I to NK cells for the purpose
of licensing? Current data would suggest that there is no single cell type responsible for
licensing of NK cells. Fetal liver and BM chimera experiments suggest that both
hematopoietic and non-hematopoietic compartments play a role (60, 61). Transgenic
expression of H2Dd in liver, testis, and intestine, with very low expression levels in
thymus, spleen, and kidney, did not induce NK cell licensing (62). However, all of these
studies are complicated by the fact that mosaic expression of MHC class I induces
tolerance of NK cells to MHC class I-deficient cells (63). In vitro developmental studies
suggest that a stromal cell is required for expression of the Ly49 receptors, apparently in
an MHC-dependent manner (59, 64). However, whether stromal cells are actually
necessary for NK cell licensing is not known. In sum, the minimum requirements for
licensing of NK cells have not yet been identified.

Cis and trans engagement of Ly49 receptors with MHC class I
Ly49 receptors have the curious ability to engage their MHC ligand in cis, where
Ly49 and MHC class I are expressed on the same cell, as well as in trans, where Ly49
and MHC class I are expressed on different cells (43). Importantly, as the cis and trans
binding sites of Ly49 receptors are the same (“site 2”, (65-67)), cis engagement by Ly49
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prevents the receptor from interacting with MHC class I in trans (43). Indeed, a recent
study has shown that cis interactions of Ly49 with MHC class I are stable and not
displaced by MHC class I presented in trans (68). Interestingly, cis interactions of Ly49
with MHC class I molecules reduce the ability of NK cells to receive inhibitory signals
from target cells. NK cells that expressed both Ly49A and its cognate ligand H2Dd were
able to kill H2Dd-expressing tumor cells whereas Ly49A+ NK cells lacking H2Dd, and
therefore lacking cis interactions, were inhibited from killing (43).
Structural studies by the Mariuzza and Margulies groups suggest that the
homodimeric Ly49 receptors have two conformations, termed open and closed (69, 70).
The open conformation, seen in the Ly49C crystal structure (71), is symmetric and can
bind two MHC class I molecules. The closed conformation, seen in the Ly49A crystal
structure (65), is asymmetric and can bind only one MHC class I molecule. NMR studies
have shown that Ly49 molecules can shift from one conformation to the other, leading to
the hypothesis that closed and open conformations may correspond with cis and trans
interactions of Ly49 receptors (69). Indeed, recent work indicates that this is the case.
Ly49A can bind two MHC class I molecules in trans but only one MHC class I molecule
in cis (72). The drastically different structural conformations required for those two types
of MHC class I engagement may influence the signals mediated by inhibitory Ly49
receptors.
More recently, Held and Mariuzza have proposed that cis interactions of Ly49
receptors with MHC class I prevents the recruitment of the Ly49 receptor to the
immunological synapse (44). By sequestering inhibitory Ly49 receptors away from the
synapse, cis interactions make the NK cell more sensitive to activation stimuli. In
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essence, this hypothesis is very similar to the receptor calibration model described above
and shares the same shortcomings, namely that this model fails to explain the
hyporesponsive phenotype of MHC class I-deficient NK cells.
Subsequent research by the Held group indicates that cis engagements of Ly49
with MHC class I are indeed required for NK cell licensing (73). Specifically, NK cells
that expressed an engineered Ly49A molecule whose rigid stalk allowed trans but not cis
engagements with MHC class I were not licensed. In addition, Chalifour et al suggest that
Ly49 receptors that are not bound to MHC class I in cis produce a tonic inhibitory signal
that terminates upon cis engagement of Ly49. While NK cells expressing a wild-type
Ly49A transgene in the absence of a MHC class I ligand exhibited a reduced response to
MHC class I-deficient target cells, NK cells expressing a Ly49A molecule with a mutated
ITIM responded as well as non-transgenic NK cells. This finding indicates that
unengaged Ly49 receptors produce an ITIM-dependent inhibitory signal.
There has been some debate regarding the roles of cis engagement and true
decrease in Ly49 receptor surface expression in producing the observed downregulation
of receptors detectable by flow cytometry. Andersson et al reported that acid treatment of
NK cells restores Ly49A expression to 43% of levels on NK cells lacking cis ligand, and
they ascribe the remaining 57% decrease to true down-regulation of surface expression
(74). This is in contrast to data presented by Doucey et al, which showed almost complete
recovery of Ly49 levels with acid treatment (43). Notably, in similar experiments, we
have found that cis engagement between Ly49 and MHC class I may protect the MHC
class I molecule from denaturation (AHJ and WMY, unpublished observations). The
extent of cis binding may therefore be underestimated in calculations based on the acid
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stripping technique. Nonetheless, it is possible that mechanisms in addition to cis
engagements may induce the downregulation of surface Ly49 receptors.

NK cell licensing: analog or digital?
While NK cell licensing is well established for strong ligands of inhibitory Ly49
receptor, the effect on NK cell licensing of moderate or weak Ly49-MHC class I
interactions remains unclear. The relationship between Ly49-MHC class I affinity and
strength of licensing is particularly interesting given the vast polymorphism of both MHC
class I genes and inhibitory NK receptors. Does a Ly49-MHC class I interaction above a
given threshold lead to full licensing whereas interactions below the threshold have no
effect on licensing (a digital model), or is the strength of NK cell licensing proportional
to the strength of the Ly49-MHC class I interaction (an analog or quantitative model)?
Since Ly49 receptors also mediate effector inhibition, are the Ly49-MHC class I
engagement sensitivities of NK cell licensing and effector inhibition the same or
different? Answers to these questions would improve our understanding of the behavior
of NK cell populations in the diverse MHC contexts of outbred populations.
Recent studies have attempted to elucidate the analog or digital nature of NK cell
licensing by investigating the potency of NK cell subsets in mice expressing one, two, or
three MHC class I alleles (75, 76). Joncker et al reported that NK cell potency increases
with the number of self-specific inhibitory receptors: NK cells expressing two different
self-specific inhibitory receptors respond more robustly to stimulation than NK cell
subsets expressing only one self-specific inhibitory receptor (76). In addition, Brodin et al
used flow cytometry to assess the NK cell potency of Ly49-monopositive populations in
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mice expressing selected MHC class I alleles (75). They found that the Ly49Amonopositive NK cell subset of mice expressing only H2Dd, a known licensing ligand for
Ly49A (27), exhibited a more robust response to NKG2D stimulation than the
corresponding cells from mice expressing only H2Db, which in turn responded more
strongly than cells from mice lacking MHC class I. Based upon these and other data,
Brodin et al and Joncker et al propose an analog (“rheostat”) model of licensing, in which
the potency of a given NK cell subpopulation is modulated by the nature and number of
Ly49-MHC class I interactions. Data from studies of human NK cells also support a
quantitative model of licensing. For example, Yu et al and Yawata et al both report that
NK cell potency was higher among NK cells that expressed two self-specific KIRs than
among NK cells expressing only one self-specific KIR (2, 77). Thus, the available data
support quantitative modulation of potency of an individual NK cell based upon the
number of self-MHC-specific inhibitory receptors that it expresses.
On the other hand, evidence of the effect of engagement of a single inhibitory
receptor by different MHC alleles is limited, although the simplest prediction of the
rheostat model is that stronger interactions should produce more potent NK cells.
However, most studies of murine NK cells have been confined to just two H2 haplotypes,
H2b and H2d. The most detailed study, by Brodin et al, used H2Kb, Db, and Dd as model
MHC class I molecules. Whereas Ly49A does not bind H2Kb, and has occasionally but
not consistently been reported to bind weakly to H2Db in older binding studies (e.g., (78,
79)), Ly49A binds strongly to H2Dd. Thus, only a very limited selection of MHC class I
alleles has been used to study the putative quantitative nature of licensing through a
single self-MHC-specific receptor.
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More detailed knowledge of the contribution of individual NK cell inhibitory
receptors to licensing in different MHC contexts may have clinical implications. Human
NK cells display properties consistent with licensing in that NK cells expressing a killer
immunoglobulin-like receptor (KIR) with specificity for self-HLA molecules exhibit
more robust responsiveness than NK cells without self-HLA specific receptors in the
same individual (2, 33, 80). With increasing numbers of studies reporting a connection of
NK cell inhibitory receptors and licensing with human anti-viral and anti-cancer
responses (e.g., (81-83)), a better understanding of licensing in mice should provide
insight into human NK cell biology and its effects on human health and disease.
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Figure 1. Licensing of NK cells. An NK cell must engage self-MHC class I in order to
become licensed. NK cell licensing requires the ITIM signaling motif (indicated by an
asterisk) of the inhibitory Ly49 receptor. Ly49 receptors can engage MHC class I either
in cis or in trans, but the roles of these two types of Ly49A engagement in NK cell
licensing are not yet clear. An NK cell that cannot engage self-MHC, either because it
does not express any inhibitory NK receptors capable of binding any self-MHC class I
molecule or because the host lacks MHC class I (e.g., !2m-/- mice), remain unlicensed.
There is no known molecular marker of licensing, hence licensing of NK cells is assessed
in an ex vivo stimulation assay using plate-bound antibodies against NK1.1, an activation
receptor expressed by all NK cells on the B6 and B10 backgrounds. In these assays,
licensed NK cell populations make IFN" at a high frequency whereas unlicensed NK
cells make IFN" at a lower frequency.
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Mice. MHC-congenic mice, including C57BL/10 (H2b), B10.D2 (H2d), B10.BR
(H2k), B10.D1 (H2q), B10.RIII (H2r), and B10.S (H2s), as well as TAP1-/- mice and RosartTA mice (B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae/J) were purchased from The Jackson
Laboratory (Bar Harbor, ME). H2Kb-/- H2Db-/- (Kb-/- Db-/-) mice were purchased from
Taconic Farms (Germantown, NY). Dd-transgenic Kb-/- Db-/- mice were obtained by
crossing Dd-transgenic mice (D8, expressing a Dd genomic construct with transgenic Dd
expression comparable to H2d mice) provided by D. Margulies (NIAID, Bethesda, MD)
to Kb-/- Db-/- mice. To generate offspring homozygous, hemizygous, or nullizygous for the
Dd transgene, Kb-/- Db-/- mice homozygous for the Dd transgene were bred to Kb-/- Db-/mice, and F1 mice were then bred together. Similarly, B10.BR mice were bred to Kb-/- Db/-

mice to produce mice hemizygous for the H2k class I locus. These mice were then

compared to commercially obtained parental strains. For the B10.RIII F2 hybrid mouse
experiments, B10.RIII mice were mated to C57BL/6 mice. The subsequent (B10.RIII x
C57BL/6)F1 hybrid mice were sibling mated to produce F2 hybrid mice which were then
screened using microsatellite markers for the H2 locus and chromosome 10 from
B10.RIII mice. Microsatellite screening was performed by the Rheumatic Disease Core
Center’s Speed Congenics Lab at Washington University School of Medicine. All mice
were used in accordance with institutional guidelines for animal experimentation.
Antibodies and flow cytometry. The following antibodies and reagents were
purchased from BD Biosciences (San Jose, CA): Pacific Blue and PerCP Cy5.5 anti-CD3
(145-2C11); PerCP Cy5.5 anti-CD19 (1D3); APC and PE Cy7 anti-NK1.1 (PK136);
Alexa 488, PE, or PE Cy7 anti-IFN! (XMG1.2); FITC anti-H2Dk (15-5-5); PE anti-H2Dd
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(34-5-8S); PE anti-H2Kb (AF6-88.5); and PE- and APC-conjugated streptavidin. PE- and
APC-conjugated anti-H2Kb-ova peptide-in-groove mAb were purchased from
eBioscience (San Diego, CA). Anti-Ly49A clones A1 and JR9 were produced from
hybridomas as previously detailed (22, 84), purified, and labeled with biotin or FITC
using standard protocols. For gating on Ly49A-monopositive NK cells, the following
antibody clones were used to exclude other inhibitory NK cell receptors: 4LO33 (antiLy49C; produced from a hybridoma kindly provided by Suzanne Lemieux, Institut
National de la Recherche Scientifique-Institut Armand-Frappier, Laval, Quebec,
Canada); 5E6 (anti-Ly49C/I; BD); HBF-719 (anti-Ly49F; BD); 4D11 (anti-Ly49G2; BD
or hybridoma from ATCC); YLI-90 (anti-Ly49I; BD); 16a11 (anti-NKG2A;
eBioscience). The commercially available antibodies were purchased in PE-conjugated
form, except 4D11 (APC). Homemade 4LO33 and 4D11 were used in biotinylated form
with streptavidin-PE. Anti-NK1.1 clone PK136 (ATCC) was grown from the hybridoma
and purified according to standard protocols. For flow cytometric analysis, RBC-lysed
single-cell suspensions of splenocytes were stained in the presence of 2.4g2 supernatants.
Samples were analyzed on a FACSCanto (BD Biosciences), and the data were analyzed
using FlowJo (TreeStar, Inc., Ashland, OR)
NK cell stimulation assays. Splenocytes were harvested and stimulated with 2 µg
or 5 µg PK136 (anti-NK1.1) monoclonal antibody (or, in some cases, PK136 ascites)
essentially as previously described (27). Briefly, 6-well tissue culture-treated plates were
coated with purified mAb in 1 mL PBS. 107 naïve splenocytes were added to the washed
plates and incubated at 37 C and 5% CO2 for 1 hour, and then further incubated in the
presence of brefeldin A (GolgiPlug, BD Biosciences) for an additional 7 hours. IFN! was
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detected by intracellular cytokine staining and flow cytometry as described previously
(56). For co-culture experiments, 5 x 106 splenocytes from each of two mice were pooled
into the same well. In some experiments, alternative stimuli were used, including antiLy49H mAbs (3D10), anti-Ly49D mAb (4e5), and IL-12 and IL-18. For anti-Ly49H and
–Ly49D stimulation, plates were coated with 5µg of mAb. IL-12 and IL-18 were added
to a final concentration of 10 ng/mL and 50 ng/mL, respectively. Stimulation with PMA
and ionomycin at final concentrations of 0.5µg/mL and 4 µg/mL, respectively, was used
as a positive control.
Ly49A tetramer synthesis and binding assays. Recombinant soluble BirA-tagged
Ly49A monomers were synthesized, purified, and refolded as previously described from
a construct generously provided by N. Matsumoto (University of Tokyo, Tokyo, Japan)
(78). The monomers were tetramerized with APC-conjugated streptavidin (BD
Biosciences) immediately prior to cell staining.
Ly49A+ LAK cell preparation. Splenocytes were harvested from H2Dd-transgenic
Kb-/- Db-/- mice, and nylon wool column non-adherent cells were isolated and cultured in
R10 media supplemented with 800 U/mL IL-2. On day 6, Ly49A+ and Ly49A- LAK cells
were isolated as previously described (22). Cells were used on Day 9. Ly49A+ LAK cell
purity (Ly49A+ NK1.1+ CD3-) ranged from 79.1 to 93.4% (mean ± SD: 87.3 ± 5.5%), and
Ly49A- LAK cell purity (Ly49A- NK1.1+ CD3-) ranged from 88.7 to 95.5% (mean ± SD:
92.6 ± 2.3%).
Cytotoxicity assays. Four-hour 51Cr-release assays were performed according to
standard protocols using Day 9 Ly49A+ or Ly49A- LAK cells as effectors. In some
experiments, splenocytes from mice treated with poly-I:C (InvivoGen, San Diego, CA)
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were used as effector cells. Con A blast target cells were produced by culturing
splenocytes in R10 plus 6 µg/mL concanavalin A for two days. JR9 F(ab’)2 fragments for
blocking experiments were produced from purified antibody using Pierce Mouse IgG1
Fab and F(ab’)2 Preparation Kit (Thermo Scientific). MAR F(ab’)2 fragments were
produced by conventional pepsin digestion and protein A purification.
In vivo peptide administration. The VSV-8 peptide RGYVYQGL was purchased
from Sigma (St. Louis, MO), and the NUbO68–75 peptide VNVDYSKL and its variant
VNVDASKA were purchased from EZBiolab (Westfield, IN). The peptides were
reconstituted in a minimal volume of PBS under sterile conditions. For ip peptide
administration, peptide concentrations were adjusted with sterile PBS to the appropriate
volume. For peptide administration by osmotic pump (ALZET, Cupertino, CA), peptides
were used at the stock concentration in PBS, 40 mM for VNVDYSKL and 10 mM for
VDNDASKA. This produced delivery rates of 480 nmol/day and 120 nmol/day for
VNVDYSKL and VNVDASKA, respectively. Osmotic pumps were primed, loaded, and
surgically implanted following manufacturers instructions. Surgical procedures followed
institutional guidelines and recommendations for sedation and anesthesia. The mice were
monitored daily during the entire course of the experiment.
Kb-ova SCT III and H2Dd tetramer synthesis. A Kb-ova SCT III tetramer cDNA
construct was produced by cloning a BirA tag onto the Kb-ova SCT III cDNA sequence
of a plasmid with a pET21a backbone, kindly provided by the Hansen Lab (Washington
University School of Medicine). This construct was transformed into BL21 (DE3) RIL
competent cells. The H2Dd heavy chain and "2m constructs were kinds gifts of D.
Margulies (NIAID, Bethesda, MD). For protein production, transformed BL21 (DE3)
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RIL cells were grown overnight in 100 mL Luria broth (LB) supplemented with 100
µg/mL ampicillin and 50 µg/mL chloramphenicol. The overnight culture was then used
to inoculate 3L of LB without antibiotics. After the culture had grown to an OD of
approximately 0.8, protein production was induced by the addition of IPTG to a final
concentration of 1 mM. The bacteria were harvested by centrifugation after an additional
four hours of culture. Inclusion bodies were produced and the protein refolded following
established protocols (85). The H2Dd tetramer was refolded with RGPGRAFVTI peptide
(Sigma, St. Louis, MO) from the gp160 protein of HIV. The concentrated refolding
reaction was applied to a S75 size exclusion column and eluted with sizing column buffer
(150 mM NaCl, 20 mM HEPES pH 7.4, 0.05% sodium azide). Biotinylation was
performed with BirA biotin ligase kit (Avidity, Aurora, CO) following the
manufacturer’s protocol, except for the incubation, which was carried out at 30C for 90
minutes. The biotinylated protein was purified on an anion exchange column as described
(85). The relevant fractions were pooled, concentrated, and equilibrated into PBS
supplemented with protease inhibitors (1mM EDTA, 1 µg/mL leupeptin, 1 µg/mL
pepstatin, 200 µM PMSF). Protein was quantitated by UV absorbance.
Kb-ova SCT III tetramer binding and competition assays. For simple binding
assays, 4.4 x 105 CHO cells stably transfected with Ly49C were stained on ice for 30
minutes in a reaction volume of 50 µL. The indicated final concentration of labeled
conventional H2Kb-ova tetramers, first-generation Kb-ova SCT tetramers, or thirdgeneration Kb-ova SCT tetramers were produced from 2.2 µM stocks for all tetramers.
H2Dd tetramers were used as a negative control for Ly49C binding. In the competition
assay, unlabelled third-generation Kb-ova SCT tetramers were mixed with labeled
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tetramers and then added to 5x105 CHO cells stably transfected with Ly49C in a total
staining volume of 50 µL. A final concentration of 8.8 nM of labeled tetramer was used
with the indicated amount of unlabeled tetramer.
Construction of rtTA transgene. The rtTA transgene was produced by excising the
PCMV promoter from pTetOn Advanced (Clontech, Mountain View, CA) with AccI and
EcoRI and inserting a short adaptor segment containing DraIII and SalI sites. (All
restriction enzymes were purchased from New England Biolabs, Ipswich, MA.) The
H2Kb promoter was obtained from the vector pHSE3’S3-C, a kind gift from James
Darnell (Rockefeller University, New York, NY), as a BglI SalI fragment and cloned into
the DraIII- and SalI-digested pTet-On adaptor-rtTA plasmid. The IgH enhancer element
was excised from pHSE3’S3-C with EcoRI and then Klenow-treated to produce blunt
ends. This fragment was then ligated into pTet-On Kb promoter-rtTA plasmid that had
been digested with HindIII and treated with Klenow. The completed construct was
sequenced for verification.
Construction of Kb-ova single-chain trimer (SCT) transgene. The third-generation
Kb-ova SCT construct was produced from three separate plasmids kindly provided by
Ted Hansen (Washington University School of Medicine, St. Louis, MO). First, H2Kb
exons 1 and 2 were amplified from plasmid WU649, which encodes the genomic
sequence of the first three exons of H2Kb. This fragment was then used as a reverse
megaprimer with a conventional forward primer for amplification of the 5’ region of the
third-generation Kb-ova SCT consisting of the peptide, "2m, and early H2Kb exon 1 from
the plasmid WU899, which encodes a cDNA form of the third-generation Kb-ova SCT.
The resulting 1.2 kb fragment was then digested with BstBI and PmlI and ligated into a
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similarly digested WU649 plasmid. The resulting plasmid was then digested with XbaI
and ligated into XbaI-digested WU596, which encodes the remainder of the genomic
H2Kb sequence. To clone the entire Kb-ova SCT sequence into pTRE-tight (Clontech),
the Kb-ova SCT fragment was amplified using primers carrying NotI and HindIII sites,
respectively. After digest by these enzymes, this fragment was cloned into a similarly
digested pTRE-tight plasmid. The completed construct was sequenced for verification.
Preparation of transgene DNA for injection into oocytes. The 4.5 kb Kb-ova SCT
transgene was isolated by gel purification of XhoI digestion of pTRE-tight-Kb-ova SCT
III. The SCT transgene DNA was electo-eluted from the gel fragment and recovered from
the elecrophoresis buffer using an Elutip-d column (Whatman, Kent, United Kingdom).
The transgene DNA was ethanol precipitated and resuspended in microinjection buffer
under sterile conditions. The rtTA transgene was isolated as a 5.2 kb BstZ171 and BsrBI
fragment and processed in a similar manner. Injections into C57BL/6 oocytes were
performed by the Transgenic Knock-out Micro-injection Core Facility, Washington
University School of Medicine.
PCR screening of SCT tg, rtTA tg, and Rosa-rtTA mice. SCT mice were screened
by PCR amplication of a 250 bp band by the primers (5’-TAG GCG TGT ACG GTG
GGA G-3’) and (5’-TGC CTC CAC CTC CGC TAC-3’). To identify the presence of the
rtTA gene in rtTA tg or Rosa-rtTA mice, the primers (5’-ACA AGA GCA AAG TCA
TAA ACG G-3’) and (5’-CAG CGG AAT GAC TTG GCG TTG-3’) were used to
amplify a 250 bp fragment. Both of these PCR reactions used Rag1 as an internal control
band, using primers (5’-GAG GTT CCG CTA CGA CTC TG-3’) and (5’-CCG GAC
AAG TTT TTC ATC GT-3’) to produce a 474 bp band. Homozygous or heterzogous
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Rosa-rtTA knockin mice were distinguished using a PCR protocol provided by The
Jackson Laboratory, which uses the primers (5’-AAA GTC GCT CTG AGT TGT TAT3’), (5’-GCG AAG AGT TTG TCC TCA ACC-3’), and (5’-GGA GCG GGA GAA ATG
GAT ATG-3’) to produce a 340 bp band from the rtTA knockin gene and a 650 bp band
from the wild-type Rosa locus.
SCT and rtTA Southern blots. To assess copy-numbers of each transgene,
conventional Southern blots were performed. Briefly, 4 µg of tail DNA was digested with
XbaI (SCT) or Xho I and BamHI (rtTA). The digest fragments were separated by agarose
gel electrophoresis. After depurination, denaturation, and neutralization, the DNA was
transferred to a Hybond N+ membrane (GE Healthcare, Waukesha, WI). After drying, the
membrane was hybridized to 32P-labeled a SCT- or rtTA-specific probe in the presence of
50% formamide hybridization buffer containing salmon sperm DNA. The SCT probe was
produced by PCR amplification of 650 bp fragment using primers (5’-CGG GAA TAC
AAT GGC GAC AC-3’) and (5’-GTC CCC TCC TTT TCC ACC TG-3’). The rtTA
probe was produced by PCR amplification of a 700 bp fragment using primers (5’-ACA
AGA GCA AAG TCA TAA ACG’3’) and (5’-GCA GGC AGC ATA TCA AGG TC-3’).
The probes were radiolabeled using a Rediprime II kit (GE Healthcare).
Doxycycline administration. Doxycycline (Sigma, St. Louis, MO) was
administered at 2 mg/mL in drinking water supplemented with 5% w/v sucrose or 4%
grape-flavored KoolAid (Kraft Foods, Northfield, IL). The doxycycline drinking water
was replaced every 2 to 4 days and was supplied in dark water bottles to protect the
doxycycline from light. For ip administration, doxycycline was dissolved in PBS (6
mg/mL) and filter-sterilized. Each mouse received 500 µL (3 mg) per dose.
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In vitro licensing of NK cells. Nylon wool column non-adherent cells from
doxycycline-naïve SCT tg rtTA tg "2m-/- mice were isolated and cultured in R10 media
supplemented with 800 U/mL IL-2 and 1 µg/mL doxycycline. On day 6, Kb-ova+ and Kbova- LAK cells were isolated using panning as previously described (22). Cells were used
in conventional 51Cr-release assays on Day 9.
T cell stimulation assays. For CD3+CD28 stimulation, 6-well plates were coated
with 25 µg purified anti-CD3 mAb (145-2C11). After addition of 5x106 RBC-lysed
splenocytes in 1 mL R10 media, anti-CD28 mAb was added to a final concentration of 2
µg/mL. For ConA stimulation, sterile-filtered ConA (Sigma) in PBS was added to 5x106
RBC-lysed splenocytes in 1 mL R10 media to a final concentration of 6 µg/mL. Largescale PMA/ionomycin stimulation was performed by adding PMA and ionomycin to
5x106 RBC-lysed splenocytes to a final concentration of 0.5µg/mL and 4 µg/mL,
respectively, in a total volume of 2 mL. These large-scale stimulations were incubated at
37C, 5% CO2 for one hour. BFA was then added, followed by an additional 7 hours of
incubation. The cells were then stained for intracellular IFN! production using
conventional methods. For small-scale T cell stimulation assays, 105 cells were
stimulated with PMA and ionomycin at concentrations of 0.5µg/mL and 4 µg/mL,
respectively, in a final volume of 100 µL. BFA was added after the first 15 minutes of a
four-hour incubation. Cells were then stained using conventional methods.
Statistical analysis. Statistical calculations were performed using GraphPad Prism
software (Treestar, Inc.). Statistical significance of differences between two groups was
calculated using the unpaired two-tailed t-test. Correlations between groups of values
were analyzed using two-tailed correlation regression.

32

CHAPTER 3

EFFECT OF MHC CLASS I AFFINITY ON NK CELL LICENSING
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Introduction
NK cell licensing is a mechanism of self-tolerance that requires an NK cell to
engage self-MHC class I in order to become functionally competent. In mice, NK cell
licensing is mediated by inhibitory Ly49 receptors such as Ly49A. NK cell licensing has
previously only been studied in the presence or absence of a known strong MHC class I
ligand of a given inhibitory Ly49 receptor. However, both MHC class I molecules and
inhibitory NK receptors are highly polymorphic, resulting in Ly49-MHC class I
interactions of varying affinities. How does the strength of a given Ly49-MHC class I
interaction affect licensing?
Other groups have recently proposed a “rheostat” model of NK cell licensing (75,
76). In this model, the strength of NK cell licensing is proportional to the strength of the
inhibitory input received by the cell. However, most of the work supporting this rheostat
model compared NK cells that expressed different numbers of self-specific inhibitory
receptors in a given MHC class I environment. Experiments addressing the effect of a
single inhibitory NK receptor paired with different MHC class I molecules used a very
limited selection of MHC class I alleles and lacked any binding data. Thus, whether
licensing through a given Ly49 receptor follows the rheostat model remains unclear. In
this chapter, we describe our studies of licensing of Ly49A+ NK cells in more diverse
MHC contexts. Paired with assays of Ly49A engagement in cis and in trans, these studies
elucidate the associations between strength of binding and licensing.
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Results
Licensing of Ly49A+ NK cells in MHC-congenic mice
The licensing status of NK cells must be determined functionally, as no molecular
marker of licensed NK cells has yet been identified. To assess licensing, we used a target
cell-free system of ex vivo stimulation of naïve splenocytes with immobilized monoclonal
antibodies against NK1.1, an activation receptor expressed on all NK cells of mice with
the C57BL/6 and C57BL/10 backgrounds (56). Stimulation through NK1.1 allowed us to
compare the activation of individual NK cells through a universally expressed NK cell
activation receptor, unlike target cell-based stimulation assays, which activate NK cells
through multiple receptors and pathways that are incompletely defined and may differ
from NK cell to NK cell. Intracellular cytokine staining and flow cytometry allow
simultaneous characterization of surface receptor expression and cytokine response to
stimulation. In the ex vivo NK1.1 stimulation assay, a higher frequency of licensed NK
cells produce IFN!, whereas few unlicensed NK cells produce IFN! (27).
IFN! production by bulk Ly49A+ NK cells from six MHC-congenic strains and
MHC class I-deficient (Kb-/- Db-/-) mice was measured by intracellular cytokine staining
and flow cytometry (Figure 2). To rule out possible licensing contributions by other
inhibitory receptors in these diverse MHC contexts, we also assessed IFN! production by
Ly49A-monopositive (Ly49A+ C– F– G2– I– NKG2A–) NK cells (Figures 3A and B). The
patterns of IFN! production by bulk Ly49A+ and Ly49A-monopositive NK cells were
nearly identical, indicating that they are due to the effects of licensing through Ly49A.
Furthermore, IFN! production by NK cell populations lacking Ly49A in addition to other
inhibitory Ly49 and NKG2A receptors does not reproduce the pattern, confirming that
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the IFN! production frequency by Ly49A-expressing cells is not due to the background
activity level of NK cells from a particular MHC-congenic mouse (Figure 3C). The only
exception is the H2r haplotype (B10.RIII mice), in which Ly49- and NKG2A-negative
NK cells displayed an elevated IFN! production frequency compared with the other
strains. However, as Ly49A-monopositive NK cells from H2r mice produce IFN! at a
significantly higher frequency than these Ly49- and NKG2A-negative NK cells, Ly49A
has a clear licensing effect in this MHC haplotype. (The B10.RIII strain is discussed
further in this chapter as well as in Chapter 7.)
Three MHC haplotypes (H2q, r, s) were included in which the function of Ly49A
on NK cells had not previously been analyzed. Ly49A+ NK cells from H2r mice produced
IFN! at high frequencies, suggesting that this haplotype encodes an as-yet unidentified
MHC molecule(s) able to engage Ly49A. In contrast, Ly49A+ NK cells of the H2q and
H2s MHC haplotypes produced IFN! at lower frequencies, indicating weak licensing. In
H2b mice, which express H2Db, a putative weak ligand of Ly49A, Ly49A+ NK cells
produced IFN! at a similarly low frequency, confirming that the H2b haplotype poorly
licenses Ly49A+ NK cells (75). As shown previously (27), NK1.1 cross-linking leads to a
high frequency of IFN! production by Ly49A+ NK cells from H2d mice, which express
the Ly49A ligand H2Dd, but by very few Ly49A+ NK cells from MHC class I-deficient
mice. NK cells from H2k mice, which express H2Dk, a known ligand for Ly49A, also
produced IFN! at a high frequency (70, 86).
The dotted lines in Figures 2B and 3B indicate the mean IFN! production by
Ly49A+ NK cells from mice of the H2d haplotype. As H2Dd is known to clearly license
Ly49A+ NK cells, MHC haplotypes with IFN! production frequencies above this level

36

can be considered strongly licensing MHC haplotypes for Ly49A. Three MHC
haplotypes (H2q, H2s, and H2b) fall below this line but exhibit stronger IFN! responses by
Ly49A+ NK cells than MHC class I-deficient cells. The low level of licensing of Ly49A+
cells of the H2b haplotype likely represents the same weak licensing impact observed by
Brodin et al in mice expressing H2Db either alone or in combination with H2Kb (75). By
extension, the H2s and H2q MHC haplotypes also offer weak licensing environments to
Ly49A+ NK cells.

Genetic contamination of B10.RIII strain does not affect licensing phenotype
While the MHC-congenic strains used herein have a long history as tools for the
study of lymphocyte biology, the potential for interference from incidental genetic
contamination remains. Although we do not know of genetic contamination in the other
MHC-congenic strains, the B10.RIII (H2r) strain contains a large MHC-donor RIIIderived region on chromosome 10 that correlates with increased susceptibility to models
of arthritis, independent of the MHC locus (87, 88). To test whether this genetic
contamination was responsible for the observed high frequency of IFN! production by
B10.RIII NK cells, we crossed B10.RIII mice with C57BL/6 mice to produce F2 hybrid
mice that were homozygous for RIII-derived genetic segments on either chromosome 10
or at the MHC locus. Such mice were identified by genotyping of microsatellite markers.
In the PK136 stimulation assay, Ly49A+ NK cells from mice of the H2r MHC haplotype
but lacking the RIII-derived chromosome 10 region produced IFN! at a frequency similar
to mice encoding both RIII-derived regions (Figure 4). In contrast, Ly49A+ NK cells
from mice of the H2b MHC haplotype that contained the RIII-derived chromosome 10
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segment did not produce IFN! beyond the level of H2b mice lacking the RIII-derived
region on chromosome 10. Thus, the licensing phenotype of Ly49A+ NK cells in
B10.RIII mice is not affected by the genetic contamination on chromosome 10 of this
strain.

Measurement of Ly49A-MHC class I interactions in trans
Using the panel of MHC-congenic mice that differentially license Ly49A+ NK
cells, we next investigated whether the affinity of Ly49A engagement by these MHC
haplotypes correlated with NK cell licensing. The most quantitative method to measure
the strength of interactions between proteins is surface plasmon resonance. However, to
apply this technique to our system would require cloning, expression, and purification of
every MHC class I molecules in the MHC-congenic strains, about 20 molecules in all.
Moreover, the peptide specificities of many of the MHC molecules are not know,
precluding efficient refolding of these molecules. Instead, we selected flow cytometrybased methods that used soluble Ly49A tetramers and MHC-congenic cells to provide
relative measures of affinity.
To make Ly49A tetramers, we expressed, refolded, purified, and biotinylated
monomeric, soluble, BirA-tagged Ly49A molecules using a construct and protocol kindly
provided by Naoki Matsumoto (University of Tokyo, Japan). Initially, we hoped to
measure relative off-rates of binding using the techniques of tetramer decay: the off-rate
of binding is proportional to the decay in tetramer fluorescence bound to MHC-congenic
cells. However, the off-rate of Ly49A engagement with even a known high-affinity MHC
ligand was too fast to allow for meaningful comparisons with lower-affinity MHC class I
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ligands (data not shown). Attempts to compare on-rates of Ly49A-tetramer binding using
similar methods also failed as the on-rates were too fast for useful comparisons (data not
shown). We therefore opted to use steady-state soluble Ly49A tetramer binding as our
measure of the strength of Ly49A-MHC class I engagement.
We measured relative Ly49A affinities by binding of soluble Ly49A tetramers to
naïve splenocytes from MHC-congenic and Kb-/- Db-/- mice. As expected, MHC
haplotypes that exhibited strong licensing of Ly49A+ NK cells bound more Ly49A
tetramer than cells of the haplotypes with weak licensing (Figure 5A). Surprisingly, cells
of the H2d haplotype bound much more Ly49A tetramer than any of the other MHC
haplotypes, yet its level of licensing of Ly49A+ NK cells was not higher than H2r and
H2k (Figures 2B and 3B). These results suggest that licensing is saturated by a certain
threshold of Ly49A engagement with self-MHC.

Measurement of Ly49A-MHC class I interactions in cis
Ly49A and MHC class I molecules can also interact in cis, i.e. on the surface of
the same cell (43, 74). The gold standard for measuring Ly49A-MHC class I interactions
in cis is to denature the MHC class I molecules with a brief incubation in acidic buffer,
thereby releasing bound Ly49A. However, we were unable to use these techniques on our
MHC congenic cells. First, we did not have any way to verify that all MHC class I
molecules present in the six MHC-congenic strains were equally susceptible to acid
treatment: antibodies are available only to a few of the MHC class I molecules studied in
this paper. Also, the MHC-congenic mice are not Ly49A transgenic, unlike the cells used
in acid stripping studies published by the Held group (43, 89), and assays focused solely
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on endogenous Ly49A+ NK cell populations are not adequately robust to detect
differences between our seven groups.
The extent of cis engagement can also be measured indirectly by the MFI of antiLy49A monoclonal antibodies such as A1: cis engagements block binding of the
antibody and result in a lower MFI (43). The MFI of anti-Ly49A staining of Ly49A+ NK
cells from MHC-congenic mice produces a spectrum of values, with H2d, H2r, and H2k
approaching saturation (Figure 5B). Similar results were obtained with a second antiLy49A monoclonal antibody, JR9, that is partially blocked by cis engagement of Ly49A
and MHC class I (data not shown) (43). With either antibody, the results suggest that cis
interactions of Ly49A with various MHC haplotypes are analog in character because, like
tetramer binding, nearly all pair-wise comparisons of MHC haplotypes produce a
statistically significant difference. However, the differences between the MHC
haplotypes with the lowest Ly49A surface accessibility were very small in magnitude,
suggesting that these haplotypes had reached saturation of cis binding.

Correlations of strength of licensing with strength of Ly49A-MHC class I engagements
Interestingly, putative cis engagements of Ly49A with MHC class I correlate
better with strength of licensing than does Ly49A tetramer binding, a measure of trans
interactions (R2 = 0.83 and 0.31, respectively) (Figures 5C and D). In particular, NK cell
licensing and cis engagement of Ly49A have similar saturation thresholds, suggesting
that cis engagement of Ly49A with MHC class I is a strong determinant of licensing, as
recently proposed by Chalifour et al for Ly49A and H2Dd and H2Dk (73). Curiously,
H2q, which only weakly licenses Ly49A+ NK cells, exhibits statistically significant levels
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of Ly49A tetramer binding and cis engagement of Ly49A as compared to the other
weakly licensing MHC haplotypes, H2s and H2b. This finding suggests that a threshold of
Ly49A binding beyond that of H2q must be achieved for strong licensing to occur, such
as that observed with H2k.

Discussion
Inhibitory NK receptors have two functions. As the name suggests, one function
is to inhibit activation of NK cell effector responses during encounters with healthy self
cells. The second, more recently discovered role relates to self-tolerance. In a process
termed NK cell licensing, NK cells must engage self-MHC class I with an “inhibitory”
receptor in order to attain full functional competence (27). NK cell licensing explains
how NK cells are able to detect missing self while maintaining self-tolerance despite the
complex expression patterns and MHC class I specificities of inhibitory NK receptors of
the Ly49 and KIR families.
The initial studies of licensing used mice that either expressed or lacked a known
MHC class I ligand of a given MHC class I receptor (27). However, given that MHC
molecules and inhibitory NK receptors are both highly polymorphic and that inhibitory
NK receptors bind some but not all MHC class I alleles, the natural state of both human
and mouse populations is likely to be much more complicated. The multitude of possible
pairings of MHC class I alleles and inhibitory NK receptor alleles raises a number of
questions with regard to NK cell licensing. Do only strong Ly49-MHC class I
interactions lead to licensing? Is licensing digital (on-off) or analog (gradual,
quantitative)? Is there a minimum affinity threshold for licensing? If licensing is analog,
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is there a saturation threshold for licensing, beyond which stronger interactions with
inhibitory NK receptor interactions do not translate into stronger licensing?
During the course of our studies, two other groups proposed a theory of
quantitative (“rheostat”) licensing to govern the licensing state of a given NK cell (75,
76). This theory states that the strength of NK cell licensing varies with the strength of
the licensing stimuli received by a given individual NK cell. This rheostat model of
licensing was based on data collected from NK cells that express different numbers of
self-MHC-specific inhibitory receptors. These studies indicated that NK cells that express
two self-MHC-specific inhibitory receptors respond more strongly to stimulation than
NK cells possessing just one self-MHC-specific inhibitory receptor (75, 76). While this is
an interesting and important finding, it does not address whether a single inhibitory NK
receptor, such as Ly49A, modulates the licensing status of an NK cell based upon the
strength of its interaction with MHC class I. Does a given inhibitory NK cell receptor
provide a digital on-off signal favoring licensing of the NK cell in the presence of selfMHC, or does the strength of the engagement of the inhibitory NK receptor by self-MHC
modulate the strength of the consequent licensing? A small number of experiments
presented in one report did investigate NK cells expressing a single inhibitory receptor in
the context of one, two, or three MHC class I alleles (75). However, these assays were
not very informative, because the range of MHC contexts was too narrow. In addition, no
binding assays were done, so there was no quantitation of interactions between the given
inhibitory NK receptor and its putative MHC class I ligands.
Studies to thoroughly and directly address whether the rheostat model applies to
licensing by a single inhibitory NK receptor require a larger and more diverse group of
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MHC class I molecules than offered by these previous studies of licensing. MHCcongenic mice on a C57BL/10 background represent an ideal model system in which to
study NK cells in a variety of MHC class I contexts. These mice possess the same genetic
background (except for a small region in B10.RIII mice, as discussed above), including
the same haplotype of the Ly49 gene family in the NK gene complex, which displays
profound genetic differences between inbred strains of mice (90). Moreover, these mice
allow study of MHC class I alleles that have generally not been studied in detail in NK
cell biology. Paired with studies of binding between Ly49A and the various MHC
haplotypes, this MHC-congenic system is an excellent model in which to determine the
relationship between strength of NK cell licensing and strength of binding of an
inhibitory NK receptor to MHC class I.
Our findings are largely consistent with a quantitative (rheostat) model of NK cell
licensing, with several new and important principles. First, NK cell licensing is saturated
by a relatively low apparent “affinity” of Ly49A engagement, as determined by Ly49A
tetramer binding. This is best exemplified by the H2d haplotype, whose uniquely high
level of Ly49A engagement did not translate into stronger licensing compared to MHC
haplotypes with more moderate binding to Ly49A. One possibility is that the H2d mice
(B10.D2) have some unidentified genetic defect that dampens NK cell potency
independent of NK cell licensing. However, H2Dd transgenic mice (Dd+/+) on a Kb-/- Db-/C57BL/6 background bind Ly49A tetramers nearly as well as mice expressing the
endogenous H2d/d locus and yet did not exhibit levels of licensing beyond that of B10.D2
mice (data not shown). Differences in avidity are also a possible explanation. However,
as described in Chapter 4, changes in MHC gene dosage, even of the moderate-binding
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MHC haplotype H2k, did not affect strength of licensing, indicating that the saturation
threshold of Ly49A-mediated licensing encompasses low-avidity interactions.
Previous data regarding a saturation threshold for NK cell licensing were
inconclusive in studies of NK cells expressing different numbers of self-MHC-specific
Ly49 receptors. Joncker et al reported increased NK cell potency with up to three
simultaneously expressed self-specific inhibitory receptors (76). However, Brodin et al
observed saturation of NK cell licensing by NK cells from H2b mice that expressed three
self-specific receptors: these NK cells were not more potent than NK cells expressing two
of the three receptors (75). On the other hand, the inclusion of two additional receptors,
i.e. the very small population of NK cells that expresses five inhibitory receptors,
produced a boosted response to stimulation. In contrast, our data with additional MHC
alleles demonstrate that licensing through Ly49A has an “affinity”-based saturation
threshold when examined in different MHC contexts. Additional studies are needed to
determine if this phenomenon extends to other MHC class I-specific inhibitory receptors,
which have different MHC specificities from Ly49A.
Interestingly, Ly49A surface accessibility by anti-Ly49A monoclonal antibodies,
a surrogate measure of cis interactions of Ly49A and MHC class I (43), exhibited a much
stronger correlation with NK cell licensing than did measures of trans interactions.
Importantly, the saturation pattern of putative Ly49A cis engagements coincided with
that of licensing of Ly49A+ NK cells. We cannot formally rule out that the observed
pattern of anti-Ly49A antibody binding is due to actual differences in Ly49A surface
expression. However, when interpreted as measures of cis engagements, as previously
described, these findings are consistent with a recent study by Chalifour et al, which
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reported that cis interactions of Ly49A and H2Dd or H2Dk are required for licensing (73).
Indeed, our data provide additional evidence for an important role for cis interactions in
licensing, and extend previous observations to additional MHC haplotypes.
The degree of cis binding also correlates with a phenotype of weak licensing of
Ly49A+ NK cells of H2b, H2s, and H2q haplotypes. Ly49A+ and Ly49A-monopositive
NK cells from MHC-congenic strains of the H2b, H2s, and H2q haplotypes make IFN! at
a significantly higher frequency than cells from MHC class I-deficient mice. On the other
hand, this frequency of IFN! production is significantly lower than the corresponding
cells from MHC haplotypes that strongly license NK cells (H2d, H2r, H2k). Interestingly,
the Ly49A+ NK cell populations of the H2q, H2s, and H2b MHC haplotypes do not
produce IFN! at a higher frequency than the corresponding Ly49A- populations.
Conventionally, this would argue against a licensing impact of Ly49A in these MHC
haplotypes. However, recent work indicates that unengaged Ly49A receptors actually
suppress NK cell responsiveness to stimulation (73). Our observations support this view,
as Ly49A-monopositive NK cells from MHC class I-deficient mice produced IFN! at a
lower frequency than the corresponding Ly49- and NKG2A-negative population. Thus,
our findings of similar IFN! responses by Ly49A+ and Ly49A- populations of the H2q,
H2s, and H2b haplotypes are consistent with the presence of a weak licensing interaction
for Ly49A.
In sum, the strength of NK cell licensing mediated by Ly49A is proportional to
the strength of the Ly49A-MHC class I interaction, but only up to a relatively modest
saturation threshold. In other words, NK cell licensing through a given inhibitory NK
receptor is only consistent with the rheostat model at low MHC class I affinities. In
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addition, cis engagements of Ly49A and MHC class I exhibited the same saturation
threshold as Ly49A-mediated licensing, supporting a role for cis engagements in NK cell
licensing.
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Figure 2. IFN! production by Ly49A+ NK cells varies with MHC haplotype. (A)
Representative flow cytometry dot plots of IFN! production by NK cells (NK1.1+ CD3CD19-) stimulated with plate-bound anti-NK1.1 antibody (5 µg PK136). (B) Average
frequency ± SD of IFN! production by bulk Ly49A+ NK cells (NK1.1+ CD3- CD19-)
stimulated with plate-bound anti-NK1.1 antibody (5 µg PK136). N=9 or 10 per group
except Kb-/- Db-/- (N=7). Pooled results from four independent experiments. The dotted
line indicates the mean IFN! production frequency of Ly49A+ NK cells of the H2d
haplotype, which is known to strongly license Ly49A+ NK cells. For each MHC
haplotype, the data are shown in the same rank order in Figures 2, 3, 5, and 8, according
to the MFI of anti-Ly49A staining depicted in Figure 5B. *: p<0.05; **: p<0.01; ***:
p<0.001.

47

A
H2d
10 5

H2r
26.9%

10 5

24.6%

10 5

10 4

10 4

10 4

10 3

10 3

10 3

10 2

10 2

10 2

0

0

0

10

2

10

3

10

4

10

5

10 5

17.8%

0

0

10

2

H2k

Ly49A

H2k

10

3

10

4

10

5

0

10 2

H2s
9.17%

10 5

10 3

10 4

10 5

H2b
8.59%

10 5

Kb-/- Db-/6.77%

10 5

10 4

10 4

10 4

10 4

10 3

10 3

10 3

10 3

10 2

10 2

10 2

10 2

0

0

0

0

10

2

IFN!

B

10

3

10

4

10

5

0

10

2

10

3

10

4

10

5

2.18%

0

0

10

2

10

3

10

4

10

5

0

10 2

10 3

10 4

10 5

Figure 3. The MHC-dependent pattern of IFN! production by Ly49A+ NK cells is
not due to other inhibitory NK receptors or background NK cell reactivity. (A)
Representative gating scheme for flow cytometric analysis of intracellular IFN!
production by Ly49A-monopositive NK cells (Ly49A+ NK1.1+ CD3- CD19- NKG2ALy49C- Ly49F- Ly49G2- Ly49I-). The number in the final dot plot represents the percent
of IFN!+ cells among the Ly49A+ population. (B) Average frequency ± SD of IFN!
production by naïve Ly49A-monopositive NK cells (Ly49A+ NK1.1+ CD3- CD19NKG2A- Ly49C- Ly49F- Ly49I-; Ly49G2+ NK cells were also gated out in two of three
experiments) stimulated with plate-bound anti-NK1.1 antibody (5 µg PK136). The dotted
line indicates the mean IFN! production frequency of Ly49A+ NK cells of the H2d
haplotype, which is known to strongly license Ly49A+ NK cells. N=6 or 7 per group,
pooled results from three independent experiments. See Materials and Methods for
antibody clones used. (C) Average frequency ± SD of IFN! production by Ly49ALy49C- Ly49F- Ly49I- NKG2A- NK cells (Ly49G2+ NK cells were also gated out in two
of three experiments) incubated with plate-bound anti-NK1.1 antibody (5 µg PK136).
N=6 or 7 per group, pooled results from the same three independent experiments
displayed in (B). *: p<0.05; **: p<0.01.
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Figure 4. IFN! production by NK cells from B10.RIII mice is not influenced by a
known region of genetic contamination. IFN! production by Ly49A+ NK cells from
mice expressing RIII- or C57BL/6 (B6)-derived regions on chromosome 10 or at the
MHC locus. B10.RIII mice were crossed with B6 mice, and the F2 pups were typed by
microsatellite analysis to select for mice homozygous for the RIII- or B6-derived
segments on chromosome 10 and chromosome 17, as indicated. Bars represent average
frequency ± SD of IFN! production by naïve Ly49A+ NK cells (NK1.1+ CD3- CD19-)
incubated with plate-bound anti-NK1.1 antibody (2 µg PK136). N=9 per group. Pooled
results from three independent experiments. *: p<0.05; ***: p<0.001
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Figure 5. Correlations between licensing, soluble Ly49A tetramer binding, and
putative cis binding of Ly49A. (A) Naïve splenocytes from MHC-congenic and Kb-/Db-/- mice were stained with soluble Ly49A tetramers. The histogram on the left displays
representative Ly49A tetramer staining data for one mouse in each group. The bar graph
on the right shows mean fluorescence intensity (MFI) ± SEM with N=3 for each group.
Representative of three independent experiments. (B) Naïve splenocytes from MHCcongenic mice were stained for Ly49A (mAb A1), NK1.1, CD3, and CD19. The
histogram on the left displays representative anti-Ly49A staining data for one mouse in
each group. The bar graph on the right shows MFI ± SEM of Ly49A staining of Ly49A+
NK cells (NK1.1+ CD3- CD19-) with N=3 for each group. Representative of two
independent experiments. (C) Correlation analysis of frequency of IFN! production by
Ly49A-monopositive NK cells from and Ly49A tetramer staining of MHC-congenic and
MHC class I-deficient mice. For details on data, see Figures 3B and 5B. (D) Correlation
analysis of frequency of IFN! production by and anti-Ly49A staining MFI of Ly49Amonopositive NK cells from MHC-congenic mice. For details on data, see Figures 3B
and 5B. *: p<0.05; **: p<0.01; ***: p<0.001.
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CHAPTER 4

EFFECT OF MHC CLASS I HAPLOINSUFFICIENCY
ON NK CELL LICENSING
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Introduction
MHC class I genes are co-dominantly expressed, so homozygous cells express
twice as much of a given MHC class I molecules as a heterozygous (or hemizygous) cell.
Licensing of NK cells requires MHC class I expression, but the effects of MHC class I
haploinsufficiency on licensing is unclear. Given the great diversity of MHC class I
alleles in outbred populations, MHC class I heterozygosity is very common. Since
inhibitory NK receptors bind some but not all MHC class I alleles, functional
haploinsufficiency of a MHC class I ligand of a given KIR is also common. Does this
haploinsufficiency of the MHC class ligand affect the strength of NK cell licensing? In
this chapter, we describe licensing studies in several genetic models of MHC class I
haploinsufficiency that indicate that a single copy of a MHC class I gene is sufficient for
licensing of Ly49A+ NK cells.

Results
NK cell licensing is insensitive to gene dosage of H2Dd
To address the role of avidity of the Ly49A-MHC class I interaction in NK cell
licensing, we used mice homozygous, hemizygous, or nullizygous for an H2Dd transgene
(genomic Dd construct with Dd expression comparable to H2d mice) on an otherwise
MHC class I-deficient background. As expected from the co-dominant expression pattern
of MHC class I genes, cells from mice homozygous for H2Dd (Dd tg/tg) express twice as
much H2Dd as cells from hemizygous mice (Dd tg/-) (Figure 6A). Accordingly, Dd tg/tg cells
also bind more soluble Ly49A tetramer than Dd tg/- cells (Figure 6B). However, the
licensing of Ly49A+ NK cells from Dd tg/tg and Dd tg/- mice was not significantly different
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at either of two anti-NK1.1 stimulation doses tested (Figures 6C and D). These results
indicate that saturation of NK cell licensing is maintained for high-affinity Ly49A-MHC
class I interactions even at lower avidities. Importantly, Ly49A exhibited similar cis
engagement in Dd tg/tg and Dd tg/- mice (Figure 6E), demonstrating the same correlation of
cis engagement with strength of licensing as observed in MHC-congenic mice (see
Chapter 3).

A single gene copy of H2k class I molecules, moderate-affinity ligands of Ly49A, is
sufficient for strong NK cell licensing
Since cells of the H2d haplotype have a uniquely high affinity and/or avidity for
Ly49A among the MHC haplotypes, we also developed a system based on H2k, a MHC
class I haplotype with a lower reactivity for Ly49A in MHC-congenic mice (Figure 5A).
We crossed B10.BR (H2k/k) mice with Kb-/- Db-/- (H2-/-) mice to create F1 hybrid mice
hemizygous for H2Dk (H2k/-). As expected, H2k/k cells express twice the level of H2Dk as
H2k/- cells and also bind twice as much soluble Ly49A tetramer (Figures 7A and B).
However, there was no consistent statistically significant difference in licensing among
Ly49A+ NK cells at two different anti-NK1.1 stimulation doses (Figures 7C and D).
Furthermore, cis engagement of Ly49A was similar on H2k/k and H2k/- Ly49A+ NK cells
(Figure 7E), providing yet more data that cis engagement of Ly49A has the same
saturation threshold as NK cell licensing. In sum, these data indicate that
haploinsufficiency of even a moderate-affinity self-MHC molecule has little or no effect
on NK cell licensing.
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Discussion
The studies described herein indicate that licensing of Ly49A+ NK cells occurs
just as well with one gene dose of an MHC class I ligand as it does with two. Previous
studies addressing gene dosage have focused on human systems and provide
contradictory results. In several epidemiological studies, homozygosity for a cognate
HLA allele ligand for a KIR was required for protection from infectious diseases,
whereas in other studies, one HLA allele was sufficient for protection (81, 91-93). For
example, individuals homozygous for the genes encoding KIR2DL3 and its cognate
ligand, HLA-C1, have improved resolution of hepatitis C (91). In contrast, even a single
gene dose of HLA-Bw4, when expressed with KIR3DL1, slows progression to AIDS
(93). Similarly inconsistent results were reported in studies of human NK cell stimulation
ex vivo. For example, licensing effects on KIR3DL1+ NK cells were only seen in donors
homozygous for the HLA ligand for KIR3DL1 (80). This contrasts with data presented
by others groups, in which a single copy of the HLA ligand for KIR2DL1 or KIR2DL2
(i.e. HLA-C2 and HLA-C1, respectively) was enough to induce robust licensing of the
corresponding NK cell populations (2, 33).
There are several possible explanations for the discrepancies in these human
studies. First, different KIRs may have different avidity thresholds, such that some KIRs
require homozygous expression of a cognate HLA ligand for robust licensing. However,
a single KIR, KIR3DL1, was found to require homozygous expression of its ligand HLABw4 in ex vivo stimulation studies, yet conferred a protective effect against progression
to AIDS even in individuals that were heterozygous for HLA-Bw4 (93).
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Second, in the epidemiological studies, individuals that are homozygous and
heterozygous for HLA ligand of a given KIR are often pooled together into the same
experimental group (“individuals with at least one ligand”), making it impossible to
distinguish differential effects of one versus two gene doses of cognate HLA ligands of a
given KIR. Moreover, human NK cell studies generally divide the HLA alleles into two
broad categories representing HLA molecules that generally do or do not bind the KIR of
interest. The HLA typing is often based on binding by a group-specific monoclonal
antibody, not sequencing for identification of exact alleles. With this type of
categorization, the strength of the interaction between the KIR of interest and the various
alleles of the cognate HLA ligand group may vary widely. As described for murine NK
cells in Chapter 3, these differences in KIR affinity may result in different strengths of
NK cell licensing and thus introduce variability in the groups that reduces the sensitivity
of the assay to detect licensing effects. Furthermore, individuals who are homozygous for
HLA genes belonging to a particular group are more likely to express an HLA allele with
high affinity for a given KIR. This in turn increases the likelihood that the individual will
have strongly licensed NK cells compared with individuals who have only one potential
HLA ligand allele. In short, the finding that homozygosity of HLA expression is
necessary for licensing in some studies may be a result of imprecise categorization of
HLA alleles.
Caution must also be exercised in extrapolating the details of studies of licensing
of Ly49-expressing murine NK cells to KIR-expressing human NK cells and vice versa.
For example, KIRs and Ly49 receptors may use different biophysical mechanisms for
licensing. Accumulating evidence indicates that cis interactions determine licensing of
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murine NK cells (73). Since there is no evidence that KIRs can engage HLA molecules in
cis, this mechanism is less likely for human NK cell licensing (44). Different mechanisms
of MHC class I engagement may explain why some KIRs require cognate HLA ligand
homozygosity to produce a detectible licensing phenotype whereas Ly49A mediates
licensing even in MHC class I haploinsufficient settings.
In fact, the ability of Ly49A to mediate strong licensing even with just one gene
dose of an MHC class I ligand may be explained by differences in relative surface
expression levels of MHC class I and Ly49A. In studies of MHC class I (H2Dd) transfer
from donor cells to Ly49A+ NK cells, H2Dd levels reached a maximum of 16 to 30% of
endogenous levels (94, 95). These data suggest that endogenous MHC class I molecules
outnumber Ly49A receptors by several-fold on the surface of NK cells. In this way, high
avidity may compensate for the moderate affinity of some MHC class I molecules for
Ly49A such that even moderate Ly49A ligands induce robust licensing. This effect may
be especially strong for cis binding of Ly49A and MHC class I, since cis binding occurs
in an essentially two-dimensional environment. Furthermore, if cis binding determines
licensing and cis binding is overwhelmed by the number of MHC class I molecules, then
decreasing the number of MHC class I molecules while maintaining the same affinity
should not affect the degree of licensing. Indeed, these are the results observed in Ly49A+
NK cells from mice expressing one versus two copies of an H2Dd transgene or
endogenous H2k class I locus. Future quantitative studies are needed to confirm this
hypothesis.
Mice with different gene doses of an MHC class I ligand provide an interesting
contrast to studies of mice with chimeric expression of an MHC class I molecule. While
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haploinsufficiency of H2Dd produced fully functional Ly49A+ NK cells, chimeric
expression of H2Dd on even as many as 80% of cells failed to license Ly49A+ NK cells,
as NK cells from these mice were incapable of rejecting H2Dd-deficient cells (63).
Interestingly, the unlicensed state NK cells from H2Dd-chimeric mice was reversed by
separating H2Dd+ and H2Dd- NK cells for 24 hours after incubation together (or apart) in
IL-2 for four days (63). Thus, while NK cells are licensed by half-maximal levels of
MHC class I on all cells, as shown herein, the lack of a given MHC class I molecule on
even a fraction of cells can greatly impact the licensing status of NK cells. The molecular
basis of this discrimination remains unknown.
Since half-maximal MHC class I expression is sufficient for NK cell licensing,
the minimum MHC class I avidity threshold of Ly49A-mediated NK cell licensing has
still not been determined. Is this avidity threshold the same for high- and moderateaffinity MHC class I ligands of Ly49A? Is strength of licensing proportional to MHC
class I expression below this MHC avidity threshold, or are NK cells simply unlicensed?
Investigating these issues will require a system of fine control of MHC class I expression.
We hope that the inducible MHC class I expression system described in Chapter 6 may
fulfill these requirements and provide answers to our remaining questions about MHC
class I avidity and NK cell licensing.
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Figure 6. Licensing of Ly49A+ NK cells is not affected by haploinsufficiency of an
H2Dd transgene. (A) H2Dd expression on splenocytes from mice homozygous (red),
hemizygous (blue), or nullizygous (green) for a Dd transgene. Each histogram represents
one mouse. Representative of four independent experiments. (B) Ly49A tetramer staining
of splenocytes, histograms colored as in A, from a single experiment. (C) Frequency of
IFN! production by anti-NK1.1-stimulated (5 µg PK136) Ly49A+ NK cells from mice of
the indicated Dd transgene genotype. Similar results were obtained when Ly49C, I, and
G2+ cells were gated out of the analysis. Frequency was normalized to the average
frequency of IFN! production by Dd tg/tg Ly49A+ NK cells in each experiment. Each
symbol represents one mouse, pooled from two independent experiments. (D) As in (C),
except at a stimulation dose of 2 µg PK136. (E) MFI ± SEM of anti-Ly49A staining
(mAb JR9) on Ly49A+ NK cells from littermates of the indicated Dd transgene genotype.
N=4 or 6 per group. Representative of three independent experiments.
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Figure 7. Licensing of Ly49A+ NK cells is not affected by haploinsufficiency of H2k
MHC class I genes, moderate-affinity ligands of Ly49A. (A) H2Dk expression on
splenocytes from mice homozygous (red), hemizygous (blue), or nullizygous (green) for
endogenous H2k class I genes. Each histogram represents one mouse. Representative of
three independent experiments. (B) Ly49A tetramer staining of splenocytes, histograms
colored as in E, from a single experiment. (C) Frequency of IFN! production by antiNK1.1-stimulated (5 µg PK136) Ly49A+ NK cells from mice of the indicated MHC class
I genotype. Frequency was normalized to the average frequency of IFN! production by
H2k/k Ly49A+ NK cells in each experiment. Each symbol represents one mouse, pooled
from three independent experiments. (D) As in (C), except at a stimulation dose of 2 µg
PK136. (E) MFI ± SEM of anti-Ly49A staining (mAb JR9) on Ly49A+ NK cells (NK1.1+
CD3- CD19-) from mice of the indicated MHC class I genotype. N=5 and 6 for the H2k/k
and H2k/- groups, respectively. Results from a Kb-/- Db-/- mouse is shown for reference.
Representative of three independent experiments.

64

A

B

100

80

80

60

60

% of Max

% of Max

100

40

40

20

20

0

0
0

10 2

10 3

10 4

0

10 5

D

E

10 3

10 4

Ly49A
tetramer

H2Dk

C

10 2

10 5

CHAPTER 5

MHC SPECIFICITY AND SENSITIVITY OF
LY49A-MEDIATED EFFECTOR INHIBITION
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Introduction
Ly49A has two functions on NK cells: (1) licensing, and (2) inhibition of effector
function, i.e., the inhibition of target cell cytotoxicity in the presence of a target cell
ligand for Ly49A. However, whether licensing and effector inhibition use the same
signaling cascades is not known. This issue is further complicated by the fact that Ly49
receptors can engage MHC class I both in trans and in cis. The binding site for Ly49A on
MHC class I are the same for both of these binding orientations, i.e. “site 2” (65, 67, 96).
While effector inhibition by definition requires trans engagement of Ly49 receptors,
recent studies suggest that NK cell licensing is mediated, at least in part, by cis
interactions of Ly49 receptors with MHC class I (73). These potential differences in
mechanism raise the possibility that the MHC specificities and sensitivities of NK cell
licensing and effector function may differ. In this chapter, we describe experiments to
assess whether these two functions of Ly49A share the same MHC specificities and
avidity thresholds. We found that while the MHC specificities were largely the same,
effector inhibition was more sensitive to MHC class I engagement than NK cell licensing.

Results
Design and development of the effector inhibition assay
To determine whether effector inhibition correlates with MHC haplotype in the
same way as licensing, we assessed inhibition of Ly49A+ effector cells by Con Aactivated blasts from MHC-congenic mice in traditional 51Cr-release cytotoxicity assays.
As effector cells, we used Ly49A+ lymphokine-activated killer (LAK) cells cultured from
splenocytes of H2Dd-transgenic Kb-/- Db-/- mice. Because these effector cells developed in
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a licensing MHC background for Ly49A NK cells, they maximize the potency of the
resulting Ly49A+ LAK cells. Importantly, using the same pool of effector cells in all
wells in each experiment eliminated licensing as a cause of differences in cytotoxicity.
Since only a small percentage of NK cells express Ly49A, we needed to separate
the Ly49A+ and Ly49A- LAK cells. The current preferred approach for separating cell
populations is cell sorting by FACS. However, LAK cells do not handle this type of cell
sorting well. Despite many attempts at optimization of sorting conditions, the LAK cells
exhibited poor viability and proliferation. We therefore used a technique called panning,
which was previously used to isolate Ly49A+ LAK cells in early studies of Ly49A
function (22). Panning uses antibody-coated tissue culture flasks to capture cells that
express the molecule of interest. Following panning, adherent cells are lifted, washed
thoroughly, and cultured for an additional two days to allow clearance of any remaining
anti-Ly49A antibody, which might otherwise interfere with engagement to MHC class I
on the target cells. Ly49A+ LAK cell purities following panning ranged from 79.1 to
93.4% (mean ± SD: 87.3 ± 5.5%). To make the target cells, splenocytes were cultured in
media containing ConA for two days. ConA is a T cell mitogen that makes otherwise
healthy splenocytes susceptible to NK cell attack.

Specific inhibition of Ly49A+ LAK cell activity by MHC-congenic target cells
The chromium release assays revealed differences in the susceptibility of MHCcongenic target cells to lysis by Ly49A+ LAK cells. Some MHC haplotypes, such as H2d,
were better at inhibiting attack by Ly49A+ LAK cells than other MHC haplotypes, like
H2b, or MHC class I-deficient cells (Figure 8A). To more easily visualize the data, we
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converted the percent specific lysis data to percent MHC-specific inhibition, normalizing
to MHC class I-deficient cells (Figure 8B). The relative levels of Ly49A-mediated
effector inhibition by different MHC haplotypes produced the same hierarchy as NK cell
licensing (Figures 2 and 3). These observed levels of lysis were Ly49A dependent,
because Ly49A- LAKs failed to produce a similar pattern of inhibition and addition of a
blocking antibody against Ly49A restored Ly49A+ LAK killing of normally resistant
MHC-congenic target cells (Figure 9).
While the general hierarchy for effector inhibition was similar to that of NK cell
licensing, we also observed some differences from NK cell licensing. For example, the
H2q haplotype robustly inhibited LAK killing yet had only a weak licensing effect.
Similarly, the H2s haplotype, which showed minimal licensing of Ly49A+ NK cells, still
inhibited Ly49A+ LAK killing significantly more than the H2b MHC haplotype. These
apparently different thresholds suggest that NK cell licensing and effector inhibition
utilize separate molecular signaling pathways or, if mediated by the same signaling
cascades, are controlled by differential threshold mechanisms.

A single gene dose of an MHC class I ligand of Ly49A is sufficient for maximal inhibition
To determine whether MHC class I haploinsufficiency affects the ability of a
target cell to inhibit killing by Ly49A+ LAK cells, we studied killing of target cells
expressing either one or two gene doses of H2Dd or the H2k class I alleles. Target cells
hemizygous for a transgene encoding H2Dd, a strong MHC class I ligand of Ly49A,
inhibited killing by Ly49A+ LAKs as well as their homozygous counterparts (Figure
10A). Similarly, target cells hemizygous for the H2k class I genes were as efficient at
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inhibiting Ly49A+ LAK cell attack as cells homozygous for these genes (Figure 10B).
Taken together, these results indicate that effector inhibition, like licensing, is saturated
by relatively low MHC class I avidity.

Discussion
Ly49A-mediated effector inhibition is more sensitive to MHC class I engagement
than is Ly49A-mediated licensing. This finding reveals a fundamental principle in our
understanding of the role of NK cell responses to normal cells as well as in pathological
contexts such as viral infection and tumor development. Some caution should be
exercised in comparing assays that use different output measures (i.e., cytokine
production versus cytotoxicity), as they may be regulated in different ways. In addition, it
is possible that IL-2 activation affects the stimulation threshold of the NK cells. For
example, previous studies have indicated that IL-2 treatment can overcome the
hyporesponsive phenotype of unlicensed NK cells (27). However, as cytokine activation
of NK cells would be most likely to raise the threshold necessary for inhibition by MHC
class I, naïve NK cells may be even more sensitive to MHC class I engagement than the
LAK cells studied herein. Furthermore, similar cytokine-rich environments are likely
present during the pro-inflammatory phase of initial immune responses. Regardless, these
findings reveal an interesting and important relationship between licensing and NK cell
effector function.
These results are also consistent with the findings of a recent study investigating
the relative contributions of licensed and unlicensed NK cells in the response to MCMV
infection (51). In this study, unlicensed cells were found to respond more robustly to
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MHC class I-expressing target cells transfected with a ligand for an activating receptor.
The licensed cells were prevented from responding because of the inhibitory signals
received from MHC class I engagement. In other words, while licensed cells respond
potently to MHC class I-deficient stimuli, MHC class I expression by target cells
efficiently prevents activation of licensed NK cells. These findings are consistent with
our results that even cytokine-stimulated NK cells (i.e., LAK cells) are extremely
sensitive to inhibition via MHC class I engagement.
The importance of this dominance of effector inhibition is illustrated by another
recent study, in which the inflammatory environment of a viral infection led to rejection
of otherwise healthy MHC class I-deficient bone marrow in mixed bone marrow chimeric
mice (97). In lethally irradiated mice reconstituted with equal numbers of wild-type and
!2m-/- bone marrow, the !2m-/- cells were eradicated within 10 days of MCMV infection.
The wild-type bone marrow cells did not decrease in proportion with the !2m-/- bone
marrow cells, indicating that inhibitory signals produced by MHC class I engagement of
inhibitory NK receptors prevented NK cells activated by the viral infection from killing
wild-type bone marrow cells. Thus, in inflammatory contexts, the ability to shut down
aberrant NK cell activation is important for maintaining self-tolerance. (The mechanisms
by which unlicensed cells, such as cells that do not express self-MHC-specific inhibitory
NK receptors, maintain tolerance to self-cells during and after viral infections remain
unclear.)
The difference in threshold of NK cell licensing and effector inhibition also has
important implications for our understanding of the signaling cascades that mediate these
events. While Ly49A-mediated effector inhibition relies mainly upon signaling initiated
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by SHP-1, the precise signaling pathway required for licensing has not been identified
(14, 98, 99). However, the differences in threshold support the view that different
signaling cascades may underlie these two functions of Ly49A. While the ITIM is known
to be required for both NK cell licensing and effector inhibition, it is increasingly evident
that ITIMs can initiate a number of diverse signaling cascades. For example, recent work
has implicated a signaling pathway involving phosphorylation of Crk in signaling by the
ITIMs of inhibitory KIRs in human NK cells (53). Clearly, ITIM signaling in NK cells is
more complex than simple recruitment of SHP-1.
The hypothesis that NK cell licensing uses a signaling cascade separate from
effector function leads to a host of new questions. First, in teleological terms, how does
an NK cell know the difference between licensing and effector inhibition? What
molecular mechanisms regulate whether a particular Ly49A-MHC class I interaction
leads to effector inhibition or licensing? One possibility is that cis versus trans
engagement of Ly49A by MHC class I may distinguish licensing interactions from
inhibitory stimuli. Cis interactions of Ly49A appear to be required for licensing of
Ly49A+ NK cells, as NK cells expressing a Ly49A molecule that could not engage MHC
class I in cis remained unlicensed (73). Further studies using a variety of Ly49A mutants
indicate that cis engagement and trans engagement induce different structural
conformations of the Ly49A molecule, including differences in the stoichiometry of the
Ly49A-MHC class I interaction (72). These structural differences may be associated with
differences in intracellular signaling cascades. In fact, one group has proposed an entirely
new way in which to view licensing by suggesting that unengaged Ly49 receptors
mediate a tonic inhibitory signal that is terminated upon cis engagement by MHC class I
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(73). The molecular components of this putative ITIM-dependent tonic signal have not
been identified.
However, data from a number of studies clearly indicate that cis interactions of
Ly49 with MHC class I are not sufficient for NK cell licensing and thus may not be the
distinguishing feature of licensing versus effector inhibition mediated by Ly49 receptors.
For example, H2Dd-expressing NK cells from H2Dd-mosaic mice are tolerant to H2Ddnegative cells (63). Only when cultured separately for a given amount of time, i.e., in an
environment with more abundant trans interactions of Ly49A and MHC class I, do the
cells acquire the ability to respond to target cells lacking H2Dd. Thus, the question
remains of how interactions of Ly49A and MHC class I can mediate both licensing and
effector inhibition, which not only have different downstream effects on the NK cell but
also feature different thresholds for strength of MHC class I engagement.
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Figure 8. Ly49A-mediated inhibition of effector function is more sensitive than NK
cell licensing. (A) Aggregate results of three independent 51Cr-release assays of Ly49A+
LAK cells from H2Dd-transgenic Kb-/- Db-/- mice killing Con A-activated MHC-congenic
splenocytes. Each condition was tested in triplicate in each experiment. (B) Specific
inhibition ± SEM of killing of MHC-congenic Con A blasts by Ly49A+ LAK cells at an
E:T of 8:1. Specific inhibition = 100 x (Specific lysis of Kb-/- Db-/- Con A blasts – Specific
lysis of MHC-congenic Con A blasts) / Specific lysis of Kb-/- Db-/- Con A blasts.
Aggregate results from three independent experiments in which each condition was
assayed in triplicate. *: p<0.05; ***: p<0.001.
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Figure 9. Ly49A-dependence of inhibition of cytotoxicity by MHC-congenic target
cells. (A) Cytotoxicity by Ly49A- LAK cells. Aggregate results of three individual 4-hour
51

Cr-release assays of Ly49A- LAK cells from H2Dd-transgenic Kb-/- Db-/- mice killing

Con A-activated MHC-congenic splenocytes. Each condition was tested in triplicate in
each experiment. (B) JR9 blockade of Ly49A restores killing of otherwise resistant
MHC-congenic target cells. Specific lysis of MHC-congenic ConA blasts by Ly49A+
LAK cells either untreated or pre-incubated with 20 !g/mL (Experiment 1) or 10 !g/mL
(Experiment 2) of anti-Ly49A (mAb JR9) or control (MAR) F(ab’)2 fragments, as
previously described.(84, 101)Specific lysis of ConA blasts from H2b mice and Kb-/- Db-/mice decreased in the presence of anti-Ly49A F(ab’)2 fragments, presumably because of
inhibitory signals produced by cross-linking Ly49A receptors. The data in each column
represent the results of triplicate wells from one experiment.
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Figure 10. Ly49A-mediated inhibition of effector function is not affected by
haploinsufficiency of MHC class I expression. (A) Specific lysis of Con A blasts
homozygous, hemizygous, or nullizygous for a Dd transgene by Ly49A+ LAK cells.
Representative of two independent experiments. (B) Specific lysis of Con A blasts
homozygous, hemizygous, or nullizygous for endogenous H2Kk and H2Dk genes by
Ly49A+ LAK cells. Representative of two independent experiments.
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CHAPTER 6

DEVELOPMENT OF MODELS OF
INDUCIBLE NK CELL LICENSING
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Introduction
Many questions remain about the kinetics and other determinants of NK cell
licensing. How long does it take for an NK cells to become licensed? Can NK cells be
licensed as mature cells? What other changes occur in conjunction with licensing, e.g.,
changes in surface receptor expression, sizes of NK cell subpopulations, or activation
states of signal transduction molecules and transcription factors? These questions are
difficult to address in wild-type mice for a number of reasons. First, licensing of NK cell
populations in wild-type mice is unsynchronized. Second, since there are no known
molecular markers of NK cells actively undergoing licensing, we cannot selectively focus
on the relevant NK cell populations, even using methods such as flow cytometry and
microscopy. In mice with static NK cell populations, we can at best compare NK cells
from mice with normal MHC class I expression (e.g. B6 mice) and mice lacking MHC
class I expression (e.g. !2m-/- mice). However, such comparisons are complicated by the
potential of other effects caused by the genetic deficiency of the MHC class I-deficient
model. For example, !2m-deficiency also affects expression and function of a number of
MHC class Ib molecules, which have important functions both within and beyond the
immune system (102). All MHC class I-deficient mice will also differ from wild-type
mice in that they have defective CD8 T cell development, which may indirectly affect
NK cells.
By creating a mouse model with inducible expression of MHC class I, we hope to
overcome many of these problems. Because the initiation of MHC class I expression is
exogenously controlled, licensing of NK cells will be synchronized. This provides easy
access to bulk NK cell populations that are in the midst of the molecular events that
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comprise NK cell licensing. A system of synchronized licensing will also allow us to
study whether mature NK cells are as capable of being licensed as developing NK cells.
Lastly, because all NK cells develop in the same MHC class I-deficient environment
prior to MHC class I expression, a system of inducible licensing provides well-matched
controls, including both NK cells that lack inhibitory NK receptors for the expressed
MHC molecule and NK cells that express a cognate inhibitory NK receptor but exist in
mice in which MHC class I expression was not induced.

Results
Administering peptide to TAP1-deficient mice to induce NK cell licensing
Our first design for a system of inducible licensing was based on models used to
study T cell biology. In their studies of T cell selection and activation, Martin and Bevan
used three consecutive daily intraperitoneal (ip) injections of 100 nmol of peptide into
TAP-deficient, TCR-transgenic mice to induce stabilization of a specific peptide-MHC
class I molecule (103). Since TAP1-deficient mice have unlicensed NK cells due to their
very low surface expression of MHC class I (25), we hypothesized that peptidestabilization of MHC class I could induce licensing of NK cells (Figure 11). To test this
hypothesis, we gave TAP1-/- mice daily ip injections of 100 nmol of one of two H-2Kbspecific peptides or an irrelevant peptide, respectively, for three days. However, no NK
cell licensing was observed (data not shown).
One concern in these experiments was that the peptide bolus was filtered out of
the bloodstream too quickly to have more than a very transient effect on class I surface
expression. A longer duration of peptide treatment might also be helpful in case NK cell
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licensing takes longer than three days. To address these issues, subcutaneous osmotic
pumps were surgically implanted to deliver peptide at a constant rate of 20 nmol per hour
(480 nmol per day) for 14 days. Again, the NK cells remained unlicensed (Figure 12A).
However, there was also no detectible increase in H2Kb in the peptide-treated mice
difference compared with mice that received PBS vehicle alone, raising the possibility
that the peptide was simply not stabilizing MHC class I (Figure 12B). Alterations in T
cell populations did not provide internal controls, as T cells in TAP1-/- mice were not
affected by peptide treatment, presumably because specific peptide-MHC-reactive T cells
are too rare in a non-TCR tg setting (data not shown).
In order to use thymocyte deletion and peripheral T cell expansion as internal
controls for effective peptide delivery and functional stabilization of MHC class I, we
crossed TAP1-/- mice to the N15 TCR transgenic line. Eight consecutive daily ip
injections of 400 nmol of the N15 TCR agonist peptide VSV-8 (RGYVYQGL) into N15
TCR tg TAP1-/- mice produced the expected changes to the T cell compartments (Figure
13). Specifically, there was a reduction in the size of the double-positive thymocyte
population, indicating deletion of peptide-reactive developing T cells, and an expansion
of the splenic CD8 T cell compartment. Consistent with our earlier findings, these
changes did not take place in TAP1-/- littermates that lacked the N15 TCR tg but were
treated in parallel with the same dose and batch of peptide.
Surprisingly, splenocytes from N15 TCR tg TAP1-/- mice, but not non-TCR tg
TAP1-/- littermates, exhibited a low but detectible level of H2Kb, perhaps as a result of
cytokine release secondary to CD8 T cell activation (Figure 14A). However, the NK cells
remained unlicensed, even in the presence of mildly elevated H2Kb, because NK cells
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from mice treated with VSV peptide did not respond more robustly to stimulation
through NK1.1 than did NK cells from TAP1-/- mice that did not receive peptide (Figure
14B).
It is plausible that the extent of class I stabilization in this system is not adequate
to provide a licensing stimulus to NK cells. Only in some experiments were we even able
to detect the increase by flow cytometry, and the greatest change, in N15 TCR tg TAP1-/mice, only produced detectible expression on less than 10% of cells (Figure 14A). While
this was enough for changes in T cell populations, it did not affect NK cell licensing. NK
cells clearly require a higher level of MHC class I than TCR-tg T cells do to produce
detectible changes. Supporting this hypothesis, studies of mice with mosaic expression of
MHC class I transgenes indicate that NK cells remain tolerant to MHC class I-deficient
cells even when such cells represent only 20% of cells (63). NK cell licensing is thus
likely to require MHC class I surface expression on the vast majority of cells. Peptide
administration to TAP1-/- mice was not able to reach this threshold level of surface class
I, even at high doses.

Design of a Tet-On system of MHC class I expression
To achieve more robust inducible MHC class I expression, we designed a “Teton” transgenic mouse model for pharmacological induction of expression of a single
MHC class I molecule (Figure 15). In the absence of doxycycline, the mice will lack all
MHC class I molecules. Upon doxycycline treatment, a single MHC class I molecule is
upregulated, leading to licensing of a single NK cell subset. The Tet-On system requires
two transgenes (Figure 16). One transgene is composed of the H2Kb promoter and IgH
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enhancer driving expression of rtTA, a doxycycline-responsive transactivator protein.
The H2Kb promoter was selected in order to provide a physiological expression pattern
for our inducible MHC class I molecule. A later iteration of this model uses a mouse with
rtTA knocked in to the Rosa locus (discussed further below). The other transgene
encodes the H-2Kb class I molecule as a single chain trimer (SCT) driven by a
tetracycline response element (TRE-tight). The rtTA transactivator and TRE-tight both
feature enhancements over early Tet-on systems to minimize leakiness of transgene
expression in the absence of doxycycline (104, 105).
The single chain trimer selected for this system consists of the class I molecule H2Kb with murine !2m and the ovalbumin-derived SIINFEKL peptide. Previous studies
have shown that a constitutively expressed Kb-ova SCT transgene can license Ly49C+
NK cells (27). In fact, on an MHC class I-deficient background, the Kb-ova SCT – Ly49C
interaction is the only licensing stimulus present (27). This low background licensing
level will permit detection of subtle changes in the Ly49C+ NK cell population. The SCT
design chosen for this particular project is the “third-generation” SCT, which features
two amino acid substitutions that increase its stability relative to the form used in the
earlier transgenic strain (106). One substitution relieves structural constraints of one of
the linkers. The other enables a disulfide bond to connect the peptide-!2m linker to the H2Kb heavy chain, thereby preventing the peptide from slipping out of the peptide-binding
groove. Improving the stability of SIINFEKL in the peptide binding groove may enhance
the ability of the SCT to interact with Ly49C, which has been shown to be somewhat
peptide-selective (107).
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Verification of binding of the third-generation SCT to Ly49C
The ability of this third-generation SCT (SCT III) to bind Ly49C has not been
previously verified. To do this, we produced a soluble form of SCT III and multimerized
it with APC-conjugated or unlabeled streptavidin. We then assessed binding of the SCT
III tetramers to CHO cells stably expressing Ly49C. For comparison, we used
conventional Kb-ova tetramers and first-generation Kb-ova SCT tetramers (SCT I), both
kindly provided by Steven Truscott of the Hansen lab. The third-generation SCT
displayed reactivity similar to the first-generation SCT, though neither of these tetramers
bound with the high reactivity of the conventional Kb-ova tetramers (Figure 17A). In
blocking experiments in which unlabeled and labeled tetramers were added
simultaneously, SCT III blocked all three types of tetramer in a dose-dependent fashion
(Figure 17B). Together, these results indicate that while the third-generation SCT does
not bind Ly49C as well as the conventional Kb-ova class I molecule, it binds
approximately as well as the first-generation SCT, which has been shown to induce
licensing of Ly49C+ NK cells in vivo (27).

Production and screening of founders of SCT and rtTA transgenic mouse lines
The construct for the SCT transgene was produced from a cDNA construct of SCT
III and a genomic construct of wild-type H2Kb and cloned into the pTRE-Tight plasmid
containing a modified tetracycline response element. The rtTA transgene was produced
by replacing the PCMV promoter of the pTet-On-Advanced plasmid encoding the nextgeneration Tet-On transactivator rtTAs-M2 with a H2Kb promoter. An IgH enhancer
element was inserted at the 3’ end of the rtTA sequence. Linearized rtTA and SCT
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constructs were submitted to the Transgenic Core facility for injection into fertilized
C57BL/6 mouse embryos. The resulting mice were screened for the presence of the
transgene by PCR. Number of insertion sites and copy number were assessed by Southern
blots. The studies described herein use rtTA rounder line #2 and SCT founder line #26,
which each carry fewer than five repeats of their respective transgene (Figure 18).

Characterization of SCT expression in SCT tg rtTA tg !2m-/- mice
After separately backcrossing the SCT tg and rtTA tg lines to a !2m-/- background,
we bred the transgenic mice together to produce rtTA tg SCT tg !2m-/- offspring. Kb-ova
expression was detected as early as 48 hours after administration of 2 mg/mL
doxycycline in the drinking water (Figure 19A). However, Kb-ova was only expressed on
a portion of the cells in the blood and spleen, even after several weeks of doxycycline
treatment (Figure 19B). There was some variability between individual mice, but over a
series of experiments, Kb-ova was expressed on approximately 10-15% of splenocytes,
with similar expression levels on T cells and B cells. Surprisingly, expression on NK
cells was consistently higher than on the other cell types, usually in the range of 20-30%.
Among NK cells, Kb-ova surface expression was higher on Ly49C+ NK cells than on
Ly49C- NK cells, although even Ly49C- NK cells had a higher frequency of Kb-ova+
cells than non-NK cell types (Figure 19C). The preference for Kb-ova expression on
Ly49C+ NK cells is likely due to MHC class I transfer via trogocytosis mediated by
specific interactions of Ly49C and Kb-ova. Trogocytosis-mediated transfer of MHC class
I molecules has been reported for inhibitory Ly49 receptors and their wild-type cognate
MHC class I receptors (94, 95).
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We would prefer to have a system with more robust Kb-ova SCT expression. We
have therefore tested different methods to improve SCT expression in the rtTA tg SCT tg
mice, such as switching from 5% sucrose in the drinking water to 4% grape KoolAid, to
better mask the bitter taste of doxycycline. We have also tested the efficacy of
intraperitoneal injections of doxycycline, which produce modestly higher frequencies of
Kb-ova SCT expression. Unfortunately, none of these approaches have produced
frequencies of Kb-ova expression above 50% among NK cells and 20% among bulk
splenocytes in the rtTA tg SCT tg !2m-/- mice.

NK cells in doxycycline-treated rtTA tg SCT tg mice are unlicensed
Since no molecular marker of licensing has been defined, we assess licensing
through ex vivo activation receptor (NK1.1) cross-linking of NK cells. Subsequent
intracellular cytokine staining and flow cytometry allow calculations of IFN" production
frequencies by specific NK cell subpopulations, such as Ly49C+ NK cells. There are two
ways to measure licensing using these data: (1) the absolute frequency of IFN"
production by Ly49C+ NK cells in mice that do or do not express an MHC ligand, and (2)
the “licensing ratio” of IFN" production frequencies by Ly49C+ NK cells versus Ly49CNK cells in the same animal. Previous studies demonstrate that mice that express a
constitutive Kb-ova SCT transgene on an otherwise MHC class I-deficient background
have Ly49C+ NK cells that are licensed according to both measures (27).
In our inducible Kb-ova SCT mice, Ly49C + NK cells from rtTA tg+ SCT tg+
!2m-/- mice treated with doxycycline do not exhibit an increased absolute frequency of
IFN" production by Ly49C+ NK cells compared to single-tg littermate controls, but they
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do have an elevated licensing ratio (Figure 20). These results appear incongruous, as
different measures of licensing seem to lead to opposing conclusions. However, we
believe they may be a consequence of the mosaic Kb-ova SCT expression pattern. Since
only a minority of cells expresses Kb-ova SCT, licensing of Ly49C+ NK cells is generally
suppressed, consistent with previous reports of mice with constitutive mosaic expression
of an MHC class I molecule (63). However, the few cells that do respond to stimulation
show evidence of a productive interaction through Ly49C, as Ly49C+ NK cells are more
likely to respond than Ly49C- NK cells. Interestingly, neither frequency of IFN"
production nor the licensing ratio differed significantly between the Kb-ova+ and Kb-ovaLy49C+ NK cell subsets (Figure 21). This result argues against a role for cis binding in
NK cell licensing. However, since no NK cell subset was robustly licensed (i.e., had a
high frequency of IFN" production in addition to an elevated licensing ratio), it is
difficult to make any firm conclusions based on this system.

Licensing of NK cells treated with doxycycline in vitro
We have recently begun investigating whether NK cells can become licensed
during culture in vitro. To do this, naive rtTA tg+ SCT tg+ !2m-/- nylon wool non-adherent
splenocytes were cultured in media containing doxycycline as well as high doses of IL-2.
A fraction of the LAK cells produced by these culture conditions expressed Kb-ova SCT,
mimicking the mosaic expression pattern observed in vivo. These cells were isolated by
panning with anti-Kb-ova antibodies and cultured for an additional two days before being
used as effector cells in 51Cr-release cytotoxicity assays against MHC class I-deficient
target cells.

89

Unfortunately, the panning technique does not work as well for Kb-ova+ cell
enrichment as it does for Ly49A+ cells. In two experiments, the frequencies of Kb-ova
SCT expression in the positive fractions were 20% and 54%, respectively (Figure 22A
and data not shown), considerably lower than the 80-90% purity obtained for Ly49A+ NK
cells (data not shown). However, despite these low purities, LAK cells enriched for Kbova SCT expression were more potent at killing !2m-/- ConA blast target cells than the
corresponding Kb-ova-depleted LAK cell fraction (Figure 22B). In the experiment with
better Kb-ova purity, the specific lysis of !2m-/- ConA blasts was nearly as high as for B6
LAKs. The observed killing was due to missing-self detection because the Kb-ova+ cells
did not kill B6 ConA blasts (Figure 22C). The Kb-ova-depleted LAK cell fraction killed
!2m-/- ConA blasts at the same low level as the control single-transgenic !2m-/- LAKs,
indicating that only NK cells that express Kb-ova SCT or are in environments rich in Kbova expression become licensed in vitro.

Expression of Kb-ova SCT in SCT tg Rosa-rtTA knock-in mice
The Rosa-rtTA strain is a knock-in mouse on a C57BL/6 background that carries a
next-generation rtTA gene in the Rosa locus. This knock-in mouse has been shown to
drive expression of target genes in many tissues, including spleen, bone marrow, and
thymus (108). To see if this rtTA gene could rescue the mosaic cellular expression
profiles of our rtTA mice, we crossed the Rosa-rtTA mice with our SCT tg !2m-/- mice.
The resulting Rosa-rtTA+ SCT tg !2m+/- mice are not useful for studying licensing since
they already express endogenous MHC class I. However, a peptide-in-groove antibody
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highly specific for H2Kb presenting the SIINFEKL (ova) peptide allowed us to detect Kbova expression in these mice in spite of the presence of background H2Kb.
When Rosa-rtTA+ SCT tg !2m+/- mice were treated with ip injections of 3 mg
doxycycline every other day for seven days (four injections), nearly all splenocytes
expressed Kb-ova (Figure 23A). This high frequency of expression was observed in two
independent experiments, and followed a unimodal pattern. Expression was robust on
bulk splenocytes as well as on individual cell populations of NK cells and T cells, though
NK cells expressed Kb-ova at a higher level than T cells (Figure 23A). Interestingly, the
Rosa-rtTA+ SCT tg !2m+/- mice, but not single-transgenic control mice, exhibited
increased expression of CD69, an activation marker (Figure 23B). The cells expressing
CD69 were mainly CD8-negative T cells. The cause of this activation is not yet clear.
However, this issue will be investigated in future Rosa-rtTA+ SCT tg !2m-/- mice, as
general immune activation and inflammation suggested by CD69 expression on T cells
could affect NK cell function and thus interfere with our licensing studies.

Discussion
A functional system of inducible NK cell licensing would allow us to ask a
number of questions that are difficult to address in wild-type systems. Beyond the basic
question of kinetics – how long does licensing of an NK cell take? – a system of
inducible licensing can also be used to investigate the molecular events surrounding NK
cell licensing. For example, what changes in gene expression occur in conjunction with
NK cell licensing? Are certain signaling molecules or transcription factors upregulated
or activated in licensed (or unlicensed) cells? Through the use of bone marrow chimeras,
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we can also assess the relative contributions of hematopoietic and non-hematopoietic cell
types to NK cell licensing in a cleaner context than previous studies. Experiments can
even be designed to test whether NK cells can be licensed ex vivo, in the absence of any
stromal environment.
The benefits and opportunities of a system of inducible NK cell licensing are
substantial, but so are the challenges in designing such a system. Because NK cell
licensing requires MHC class I expression, our designs focused on regulating MHC class
I surface expression. However, our first two attempts at producing MHC class Idependent systems of inducible NK cell licensing failed. The first, which used peptide
administration to stabilize H2Kb in TAP1-deficient mice, produced H2Kb levels that
were, at best, barely detectible. These levels were sufficient for changes in TCR tg CD8 T
cell populations but were inadequate for NK cell licensing. The second, a Tet-On
transgenic system of expression of a single chain trimer form of MHC class I, produced
mice with mosaic expression of the Kb-ova peptide-MHC. While as many as 40% of NK
cells expressed Kb-ova upon treatment of the mice with doxycycline, the licensing state
of these NK cells was too ambiguous to be informative.
Fortunately, the replacement of one of the two transgenes of the Tet-On system
yielded mice with reproducible expression of the Kb-ova molecule on virtually all
splenocytes. Upon ip administration of doxycycline every other day for a period of seven
days, Rosa-rtTA+ SCT tg !2m+/- splenocytes showed nearly uniform expression of Kbova. Curiously, an earlier experiment in which Rosa-rtTA+ SCT tg !2m+/- mice were
given 2 mg/mL doxycycline in 4% KoolAid for eight days did not produce this level of
expression. In that experiment, the two Rosa-rtTA+ SCT tg !2m+/- mice exhibited Kb-ova
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expression on 10 and 35% of splenocytes, respectively (data not shown). Thus, it seems
that oral doxycycline does not achieve the doses necessary for full expression of the SCT
transgene. It should also be noted that ip injections of 3 mg of doxycycline either every
day for three days or every other day for eight days failed to produce universal Kb-ova
expression in mice carrying our in-house rtTA tg with the SCT tg, suggesting that the
rtTA tg has some inherent defect that affects expression of Kb-ova. In sum, while more
breeding is necessary to generate Rosa-rtTA+ SCT tg mice on a !2m-/- background,
expression experiments using Rosa-rtTA+ SCT tg !2m+/- mice appear extremely
promising for future studies of NK cell licensing.
In the meantime, it is useful to consider the reasons why the two initial systems
failed to induce full NK cell licensing. Only a minority of TAP1-deficient mice that
received injections of peptide exhibited detectible stabilization of H2Kb, and even then,
the levels of expression were very low. This small increase in H2Kb was enough to
induce significant changes in the T cell compartments, as peptide-MHC-specific TCR tg
T cells were deleted in the thymus and expanded in the periphery. These changes reiterate
how exquisitely sensitive T cells are to their cognate peptide-MHC ligand. Notably, nonTCR tg T cells were not affected by peptide administration, presumably because T cells
specific for the particular Kb-peptide molecule were too rare to produce detectible
changes in thymic or splenic T cell compartments within the short time frame of the
experiment. A recent study by the Hansen lab has demonstrated that mice that
constitutively express a single type of Kb-peptide molecule can select a diverse CD8 T
cell population (109). However, the CD8 T cell compartment in these mice was smaller
than in B6 wild-type mice, indicating that the thymic selection process is less efficient in
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animals with severely restricted peptide-MHC expression. This reduced rate of
development of T cells by a single Kb-peptide molecule may explain why peptide
injections into TAP1-/- mice did not produce detectible changes in the T cell
compartments in the course of less than two weeks.
Unlike T cells, NK cells are not polyclonal, so expression of H2Kb above the
threshold necessary for licensing should produce significant changes in the Ly49C+ NK
cell subset that binds Kb-ova. However, licensing of Ly49C+ NK cells was not observed
in any of the peptide administration experiments, indicating that the barely detectable
levels of Kb stabilization produced by these models is below the level required for NK
cell licensing. Further studies are needed to verify this conclusion, as it is possible that
H2Kb was stabilized in a mosaic fashion, which is known to impair NK cell licensing
(63).
Our second design used rtTA and SCT double-transgenic mice for doxycyclineinducible expression of Kb-ova single-chain trimer. However, mice carrying the SCT
with our MHC promoter-driven rtTA tg exhibited mosaic Kb-ova expression, not the
intended universal expression. Only approximately 15% of splenocytes and 30% of NK
cells expressed Kb-ova in these mice despite attempts to improve these levels.
Interestingly, Kb-ova expression was not classically bimodal, as Kb-ova+ cells exhibited a
range of Kb-ova expression levels. Regardless, NK cells in these mice were not fully
licensed: While there was evidence of a productive Ly49C-Kb-ova interaction in the
elevated licensing ratio, Ly49C+ NK cells failed to make IFN" at a higher frequency than
Ly49C+ NK cells from MHC class I-deficient control mice.
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The finding that mice with induced mosaic expression of Kb-ova do not have
licensed NK cells is not surprising, as previous studies of mice with constitutive mosaic
expression of MHC class I did not exhibit a phenotype consistent with licensing. The
DL6-transgenic mouse line expresses a fusion protein composed of the #1 and #2
domains of H2Dd and the #3 domain of H2Ld in a mosaic fashion on 10-80% of
splenocytes, including the NK cell compartment (63). DL6 mice, which have normal
expression of H2Kb and H2Db, are tolerant to both B6 BM (i.e. lacking H2Dd) and H2Ddtransgenic B6 BM, although they can reject !2m-/- BM with normal kinetics. Similar
results were obtained in two H2Dd-mosaic mouse models created using Cre-lox systems
(60). However, administration of type I interferon inducers or estrogen receptor
antagonists were required to induce mosaicism, and these agents may affect licensing.
Notably, tolerance to H2Dd-deficient cells was also observed in vitro, but this tolerance
of DL6 NK cells to B6 lymphoblasts was reversed by separating H2Dd+ and H2Dd- NK
cells for 24 hours after incubation together (or apart) in IL-2 for four days (63). This
result suggests that continued exposure to tolerizing cells is needed to maintain tolerance.
Encouragingly, Rosa-rtTA+ SCT tg mice exhibit a unimodal elevation of Kb-ova
expression upon treatment with doxycycline. Breeding is underway to obtain Rosa-rtTA+
SCT tg mice on a !2m-/- background to assess licensing of Ly49C+ NK cells by induction
of Kb-ova expression in vivo. After the principle of inducible NK cell licensing is
established in these mice, the parameters of Kb-ova expression (e.g., surface levels and
time span) can be manipulated through changes in the doses and duration of doxycycline
treatment. These mice are also promising tools for studies of NK cell licensing in vitro, as
the problematic step of separating Kb-ova+ and Kb-ova- NK cells would be unnecessary.

95

Such studies may help us identify the minimal cellular and molecular components
necessary for NK cell licensing. We look forward with great anticipation to the many
studies planned for this new mouse model.
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Figure 11. Schematic of peptide-induced licensing of NK cells in TAP1-/- mice.
TAP1-/- have low surface expression of MHC class I due to defective peptide loading.
Consequently, NK cells in TAP1-/- mice are unlicensed. Exogenous peptide can increase
MHC class I surface expression by binding to and stabilizing MHC class I molecules
found on the cell surface. Stabilization of H2Kb by specific peptides may lead to
licensing of Ly49C+ NK cells.
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Figure 12. Administration of an H2Kb-specific peptide does not lead to licensing of
Ly49C+ NK cells or to detectible H2Kb surface expression. (A) Osmotic pumps
containing the Kb-specific peptide VNVDYSKL, an irrelevant peptide VNVDASKA, or
PBS were implanted into TAP1-/- mice. VNVDYSKL peptide was administered at a rate
of 20 nmol per hour (480 nmol per day) for 14 days. At the end of this period,
splenocytes were isolated and stimulated with a 1:3000 dilution of PK136 (anti-NK1.1)
ascites, and IFN! production was assessed by intracellular flow cytometry. Dot plots are
gated on NK cells (NK1.1+ CD3- CD19-). Percentages indicate the frequency of IFN!
production by Ly49C+ NK cells. Representative results from one of three mice in each
group are shown. Results from peptide-naïve B6 and TAP1-/- mice from the same NK1.1
stimulation experiment are shown for reference. (B) Naïve splenocytes were stained for
H2Kb to assess peptide stabilization of MHC class I. Each histogram represents one
mouse. N=3 for VNVDYSKL and PBS. N=1 for peptide-naïve B6 and TAP1-/- controls.
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Figure 13. VSV peptide produces detectible changes in the T cell populations of N15
TCR tg TAP1-/- mice. N15 TCR tg TAP1-/- and non-tg TAP1-/- mice were given daily
intraperitoneal injections of 400 nmol (382 µg) VSV-8 peptide (RGYVYQGL) or PBS
for eight days. On day nine, (A) thymocytes and (B) splenocytes were harvested and
stained for CD4 and CD8. Dot plots are representative of two mice per group.
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Figure 14. VSV-8 peptide treatment produces low levels of H2Kb stabilization but
does not induce licensing of NK cells. (A) N15 TCR tg TAP1-/- and non-tg TAP1-/- mice
were given daily intraperitoneal injections of 400 nmol (382 µg) VSV-8 peptide
(RGYVYQGL) or PBS for eight days. On day nine, splenocytes were harvested and
stained for H2Kb. Each histogram represents one mouse. Numbers listed to the right of
the histogram indicate the H2Kb MFI values for each mouse in each group. (B)
Splenocytes were stimulated with 5 µg PK136 (anti-NK1.1) and assessed for IFN!
production by intracellular flow cytometry. Cells shown are gated on NK cells (NK1.1+
CD3- CD19-). The percentage in each plot indicates the frequency of IFN! production by
Ly49C+ NK cells.
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Figure 15. Schematic of doxycycline-induced expression of Kb-ova single-chain
trimer (SCT) to license Ly49C+ NK cells. In the absence of doxycycline, these mice
lack all MHC class I molecules due to !2m-deficiency. Consequently, NK cells are
unlicensed. Upon administration of doxycycline, Kb-ova SCT expression is initiated,
potentially leading to licensing of Ly49C+ NK cells. Manipulating the dose and duration
of doxycycline treatment in this inducible system may provide information regarding the
kinetics of NK cell licensing.
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Figure 16. Schematic of rtTA and SCT gene functions. The “Tet-On” system is
composed of two genes: rtTA, a doxycycline-activated transcriptional activator, and Kbova, a third-generation MHC class I single chain trimer (SCT) composed of H2Kb, !2m,
and the ovalbumin peptide SIINFEKL (designed by the Hansen Lab, Washington
University in St. Louis). We produced transgenic mice that carry an rtTA gene under
control of an MHC class I promoter. We have also obtained mice in which the rtTA gene
has been knocked in to the Rosa locus. Both mice should produce wide tissue expression
of rtTA. The Kb-ova transgene is under control of a tetracycline response element (TRE),
to which rtTA binds in the presence of doxycycline. (A) In the absence of doxycycline,
rtTA is expressed but is inactive and does not bind to the TRE. Consequently, the Kb-ova
SCT gene is not expressed. (B) Upon treatment with doxycycline, rtTA is activated, binds
to the TRE, and induces expression of the Kb-ova SCT.
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Figure 17. Third-generation Kb-ova SCT tetramer binds to Ly49C as well as firstgeneration Kb-ova SCT tetramer but not as well as conventional H2Kb-ova
tetramers. (A) 4.4 x 105 CHO cells stably transfected with Ly49C were stained with the
indicated final concentration of labeled conventional H2Kb-ova tetramers, firstgeneration Kb-ova SCT tetramers, or third-generation Kb-ova SCT tetramers. H2Dd
tetramers were used as a negative control. (B) Unlabelled third-generation Kb-ova SCT
tetramers were added simultaneously with the indicated labeled tetramer to 5x105 CHO
cells stably transfected with Ly49C. A final concentration of 8.8 nM of labeled tetramer
were used in each condition with variable amounts of unlabeled tetramer. Results were
normalized to the MFI of unblocked tetramer staining for each tetramer.
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A

B

Figure 18. Southern blots of SCT tg and rtTA tg founders. (A) Conventional Southern
blot of genomic tail DNA (4 µg) from each of the indicated SCT tg founders digested
with XbaI, transferred to a membrane, and hybridized with a SCT-specific probe. Film
was exposed for 6 hours. (B) Conventional Southern blot of genomic tail DNA (4 µg)
from each of the indicated rtTA tg founders digested with XhoI and BamHI, transferred
to a membrane, and hybridized with a rtTA-specific probe. Film was exposed for two
days.
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Figure 19. Expression of Kb-ova SCT on rtTA tg SCT tg ! 2m-/- mice. (A) Kb-ova
expression was detected as soon as 48 hours after administration of 2 mg/mL of
doxycycline in drinking water. Bulk splenocytes, T cells (CD3+ NK1.1-), and NK cells
(NK1.1+ CD3-) are shown. Percentages of cells expressing Kb-ova are indicated. Each
histogram represents one mouse. Red and blue histograms represent rtTA tg SCT tg
!2m-/- mice. Green and orange histograms represent rtTA tg !2m-/- littermate controls. (B)
Kb-ova expression of bulk splenocytes, T cells, NK cells, and B cells after 16 days of
treatment with 2 mg/mL doxycycline in the drinking water. Red and blue histograms
represent rtTA tg SCT tg !2m-/- mice. Green and orange histograms represent SCT tg
!2m-/- littermate controls. (C) Kb-ova expression on Ly49C+ and Ly49C- cells from a
representative rtTA tg SCT tg !2m-/- mouse (red and pink, respectively) and rtTA tg !2m/-

mouse (dark green and light green, respectively) after 48 hours of 2 mg/mL doxycycline

in drinking water.
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Figure 20. Ly49C+ NK cells in mice with induced mosaic expression of Kb-ova SCT
have a low frequency of IFN! production but an elevated licensing ratio. Mice were
treated for 16 days with 2 mg/mL of doxycycline in the drinking water, except one rtTA
tg SCT tg "2m-/- mouse, which received just water (“no doxy”). Splenocytes were then
harvested and stimulated with plate-bound PK136, and IFN! production was assessed by
flow cytometry. (A) Representative flow cytometry plots of IFN! production by NK cells
(NK1.1+ CD3- CD19-). (B) Frequency of IFN! production by Ly49C+ NK cells. Each
symbol represents one mouse, pooled from two independent experiments. The single-tg
group includes both a rtTA tg "2m-/- and SCT tg "2m-/- littermate controls. The nonfunctional transgene group includes mice from rtTA founder lines that do not produce
Kb-ova SCT expression upon doxycycline treatment. (C) The licensing ratio is the
frequency of IFN! production by Ly49C+ NK cells divided by the frequency of IFN!
production by Ly49C- NK cells. Data are taken from the same samples shown in (B). *:
p<0.05.
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Figure 21. Ly49C+ NK cells that express Kb-ova do not have a stronger licensing
phenotype than Ly49C+ NK cells that do not exhibit surface expression of Kb-ova.
Mice were treated for 16 days with 2 mg/mL of doxycycline in the drinking water.
Splenocytes were then harvested and stimulated with plate-bound PK136, and IFN!
production was assessed by flow cytometry. (A) Representative gating of Kb-ova+ and
Kb-ova- NK cells in a rtTA tg SCT tg "2m-/- mouse. (B) Frequency of IFN! production by
Ly49C+ NK cells (NK1.1+ CD3- CD19-). Each symbol represents one mouse, pooled
from two independent experiments. (C) The licensing ratio is the frequency of IFN!
production by Ly49C+ NK cells divided by the frequency of IFN! production by Ly49CNK cells. Data are taken from the same samples shown in (B).

117

rtTA tg SCT tg

A

10

5

Kb-ova+ NK cells

Kb-ova

10 4

10 3

Kb-ova- NK cells

10 2
0

0

10 2

10 3

10 4

10 5

NK1.1

B

rtTA tg SCT tg

C

rtTA tg SCT tg

Figure 22. Licensing of NK cells upon Kb-ova expression in vitro. (A) Naïve nylonwool non-adherent splenocytes from rtTA tg SCT tg !2m-/- mice, SCT tg !2m-/- littermate
controls, and B6 controls were cultured in high-dose IL-2 produce LAK cells.
Doxycycline (1 !g/mL) was added to the media of all three cultures. On day 6, Kb-ova+
NK cells were enriched from the rtTA tg SCT tg !2m-/- LAK cell culture using panning.
The Kb-ova-depleted cell fraction was also saved and cultured separately. On day 9, the
LAK cells were harvested and stained for Kb-ova to assess purity. (B) Day 9 LAK cells
shown in (A) were used as effector cells with !2m-/- ConA blast target cells in a
conventional 51Cr-release assay. (C) Day 9 LAK cells shown in (A) were used as effector
cells with B6 ConA blast target cells in a conventional 51Cr-release assay. Similar results
were obtained in a second independent experiment.
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Figure 23. Kb-ova expression in Rosa-rtTA+ SCT tg ! 2m+/- mice treated with
doxycycline. (A) Rosa-rtTA+ SCT tg !2m+/- mice (red and orange) and SCT tg !2m+/littermate controls (dark and light blue) received intraperitoneal injections of 3 mg
doxycycline every other day for seven days (four injections). On day 8, splenocytes were
harvested and stained for Kb-ova expression using 25D-1.16, which does not bind to
endogenous H2Kb molecules. Each histogram represents one mouse. Bulk splenocytes, T
cells (CD3+ NK1.1-) and NK cells (NK1.1+ CD3-) are shown. (B) CD69 expression of
cells shown in (A).
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CHAPTER 7

CHARACTERIZATION AND ATTEMPTED MAPPING
OF HYPERREACTIVITY PHENOTYPE OF
NK CELLS OF B10.RIII MICE
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Introduction
NK cells from the MHC-congenic strain B10.RIII, which carries the RIII-derived
H2r MHC locus on a C57BL/10 (B10) background, produce an unusually robust IFN!
response to stimulation through NK1.1. The phenotype of B10.RIII mice was first
noticed in plate-bound PK136 (anti-NK1.1) stimulation assays of a panel of MHCcongenic strains (see Chapter 3). The B10.RIII strain is susceptible to several models of
autoimmune disease, including collagen-induced arthritis and experimental autoimmune
uveoretinitis (110, 111). The observation of a B10.RIII-specific NK cell hyperreactivity
phenotype raised the possibility that the NK cell phenotype and autoimmune
susceptibility could be connected. If so, identifying the cause of the NK cell
hyperreactivity would not only teach us about NK cell biology but may also provide new
insight into the causes of autoimmune diseases. In this chapter, we characterize the
hyperreactivity phenotype of B10.RIII mice and attempt to map a genetic source.

Results
Characterization of the NK cell phenotype of B10.RIII mice
NK cells from B10.RIII mice (H2r on a C57BL/10 background) exhibited a
uniquely robust IFN! response to stimulation through the activation receptor NK1.1. In
B10.RIII mice, 38.9±16.2% (mean ± standard deviation) of B10.RIII Ly49A+ NK cells
produced IFN!, whereas B10.D2, an H2d strain known to license Ly49A+ NK cells,
exhibited an IFN! production frequency of 25.9±4.6% (Figure 24A). Moreover, the
average frequency of IFN! production by Ly49/NKG2A-negative cells, which lack all
MHC class I-specific inhibitory receptors, was 21.9±5.7% among cells from B10.RIII
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mice but only 14.3±7.1% and 10.2±5.5% among B10.D2 or B10 mice, respectively.
While the high frequency of IFN! production by Ly49A+ NK cells could, in theory, be
the result of extremely strong Ly49A-dependent licensing, this is unlikely. First, data
from the other MHC-congenic strains indicates that Ly49A-dependent licensing is
saturated by a relatively low threshold of MHC class I engagement. Second, B10.RIII NK
cells lacking all known MHC class I-specific inhibitory receptors also exhibited elevated
IFN! responses compared with other MHC-congenic strains. This latter result in
particular suggests instead a general hyperreactivity phenotype of B10.RIII NK cells,
independent of any superimposed NK cell licensing.
To investigate whether the strong IFN! response was specific to stimulation
through NK1.1, we measured the IFN! responses of B10.RIII NK cells to a number of
different stimuli (Figure 24B). These stimuli included cross-linking of activating Ly49D
and Ly49H receptors, IL-12 + IL-18 cytokine stimulation, and the strong non-specific
activators PMA and ionomycin, which bypass the membrane-proximal steps of immune
cell activation. B10.RIII NK cells responded more robustly than B10 NK cells to the
three types of receptor cross-linking, i.e., signaling via NK1.1, Ly49D, and Ly49H.
While these three receptors use different signaling chains (Fc"RI! for NK1.1, DAP12 for
Ly49D and Ly49H), they all rely on ITAM-dependent signaling, suggesting that a
signaling component common to these three receptors might mediate the B10.RIII
hyperreactivity. Responses to cytokine stimulation and PMA/ionomycin activation were
similar among B10.RIII and B10 NK cells, indicating that not all activation pathways are
affected by the hyperactivation phenotype of B10.RIII mice.
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To test whether this hyperreactivity phenotype affected NK cell cytotoxicity in
addition to cytokine production, we performed a 51Cr-release assay of poly-I:C-activated
splenocytes killing YAC-1 and #2m-/- ConA blast target cells. B10.RIII cells exhibited
elevated killing against both target cell types, indicating that cytotoxicity is also enhanced
in these mice (Figure 25). That both targets were killed better by B10.RIII cells provides
further evidence of a general hyperreactivity phenotype of NK cells in these mice.
Interestingly, there was no difference in killing by splenocytes from mice that did not
receive poly-I:C (data not shown).
Next, we inquired whether the NK cell phenotype is cell-intrinsic or cell-extrinsic.
To do this, splenocytes from B10 and B10.RIII mice were co-cultured during stimulation
with anti-NK1.1 monoclonal antibodies or other stimuli. The cells were then separated by
H2Kb staining during analysis of the flow cytometry data. In this assay, B10.RIII NK
cells and B10 NK cells cultured together during the stimulation produced IFN! at the
same frequency as the cells cultured separately (Figure 26). In other words, B10 NK cells
did not acquire the hyperreactivity phenotype of the B10.RIII NK cells with which they
were cultured. Thus, the hyperreactivity phenotype is cell intrinsic, effectively ruling out
a soluble or membrane-bound extracellular factor as the mediator of the phenotype.

B10.RIII T cells are also hyperreactive
Because the hyperreactivity phenotype of B10.RIII NK cells seemed to affect
several activation pathways and effector functions, we hypothesized that this phenotype
may also affect other cell types with similar functions. To test this, we assessed IFN!
production by CD8 T cells upon stimulation with antibodies against CD3 and CD28, to
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mimic endogenous engagement with TCR and co-stimulatory molecules. We also
stimulated the cells with the T cell mitogen ConA as well as PMA/ionomycin. Compared
with B10 T cells, T cells from B10.RIII mice responded more robustly to all three types
of stimulation (Figure 27). The B10.RIII T cell response to PMA/ionomycin was
especially robust. These results suggested that the phenotype identified in NK cells is also
present in T cells and is likely caused by a factor (or multiple factors) shared by both cell
types.

B10.RIII mice carry a large region of RIII-derived genetic contamination
A literature search uncovered two papers that identified a large region of parental
strain RIII-derived genetic contamination on chromosome 10 (Dong et al., Genomics
1996; Nandakumar and Holmdahl, EJI 2005). Using a collagen-induced arthritis model as
a phenotypic assay, Nandakumar and Holmdahl identified this region as being
responsible for the autoimmune susceptibility of B10.RIII mice. However, the molecular
mechanism was not elucidated, nor were the gene(s) responsible identified.
Since this RIII-derived region on chromosome 10 contributed to the autoimmune
susceptibility of the B10.RIII strain, we hypothesized that this region may also be
responsible for the lymphocyte hyperreactivity phenotype. To investigate this possibility,
we used microsatellite analysis to confirm the presence and location of this RIII-derived
region in B10.RIII mice purchased from The Jackson Laboratory (Figure 28A). The
region is very large, at least 34 megabases (32 cM) in size and comprising hundreds of
genes (Figure 28B). We also performed microsatellite analysis of the rest of the B10.RIII
genome to see if other large regions of RIII DNA remained in this strain (Figure 28A).
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Only a small number of isolated microsatellite markers diverged from the expected B10
background genotype, indicating that the chromosome 10 region was the only large RIIIderived genetic contamination in these mice.

Design of chimeric mice to assess the contributions of the chromosome 10 region and the
MHC locus to lymphocyte hyperreactivity
To assess the relative contributions of the MHC locus and the chromosome 10
region on the lymphocyte hyperreactivity phenotype, we produced a set of (B10.RIIIxB6)
chimeric mice that carried either the RIII- or B6-derived regions of chromosome 10 and
the MHC locus on chromosome 17 (Figure 29A). These four chimeric mouse strains are
referred to as 10RIII H2r, 10RIII H2b, 10B6 H2b, and 10B6 H2r, based upon their genotypes at
the region of B10.RIII genetic contamination of chromosome 10 and at the MHC locus,
respectively.

All chimeric mice lack the B10.RIII lymphocyte hyperreactivity phenotype
Surprisingly, none of the four chimeric mouse lines exhibited strong NK cell
hyperreactivity in response to anti-NK1.1 stimulation (Figure 29B). While there were
statistically significant differences between most groups, the magnitude of these
differences was relatively small. Most importantly, 10RIII H2b NK cells had a lower IFN!
production frequency than 10B6 H2b NK cells, indicating that the RIII-derived region on
chromosome 10 does not confer the NK cell hyperreactivity phenotype observed in
B10.RIII mice. The elevated IFN! production frequency of 10RIII H2r and 10B6 H2r NK
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cells compared with 10B6 H2b and 10RIII H2b NK cells may be due to differential licensing
of NK cell subsets by the H2r and H2b MHC loci.
Similarly, T cells from the four chimeric mice also failed to reproduce the
hyperreactivity phenotype upon PMA/ionomycin stimulation (Figure 29C). As observed
in NK cells, the RIII-derived region on chromosome 10 did not confer hyperreactivity to
the T cells, as 10RIII H2r and 10RIII H2b T cells produced IFN! at lower frequencies than
10B6 H2b and 10B6 H2r T cells. T cells from 10B6 H2r mice had the highest average IFN!
production frequency, but the magnitude of the difference from the other groups was very
small compared with previous observations in B10.RIII T cells (Figure 27). In short, none
of the four (B10.RIIIxB6) chimeric strains exhibited the NK or T cell hyperreactivity
observed in B10.RIII mice.
This loss of phenotype became especially apparent in direct comparisons of
B10.RIII mice purchased from The Jackson Laboratory with 10RIII H2r chimeric mice
bred on campus (Figure 30). B10.RIII T and NK cells exhibit consistently elevated,
though variable, IFN! responses compared with cells from 10RIIII H2r mice. On average,
approximately twice as many B10.RIII NK cells than 10RIII H2r NK cells produced IFN!
in response to anti-NK1.1 stimulation, and PMA/ionomycin-stimulated B10.RIII T cells
produced IFN! at an over three-fold higher frequency than 10RIII H2r T cells. Consistent
with our earlier findings, PMA/ionomycin stimulation produced similar responses by NK
cells from B10.RIII mice and the four (B10.RIIIxB6) chimeric mice. In sum, even the
(B10.RIIIxB6) chimeric mice carrying the RIII-derived regions on both chromosome 10
and at the MHC locus failed to reproduce the hyperreactivity phenotype of B10.RIII
mice.
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Discussion
NK cells from B10.RIII mice exhibit a more robust response to NK1.1 stimulation
than any of the other MHC congenic strains tested. Even NK cells that lacked all MHCspecific inhibitory receptors produced IFN! at a higher level than other MHC congenic
strains. These early findings initiated a series of experiments to further define and
potentially identify the cause of this phenotype of B10.RIII NK cells. As the B10.RIII
strain is susceptible to a number of murine models of autoimmune disease, including
models of arthritis and uveoretinitis (110, 111), we hypothesized that the B10.RIII strain
might carry a mutation that causes both lymphocyte hyperreactivity and autoimmune
susceptibility. Identifying this mutation could lead to important new insights into the
pathogenic molecular mechanisms of autoimmunity in addition to improving our
understanding of NK cell biology.
In a promising early development, further experiments on B10.RIII lymphocytes
revealed that the hyperreactivity phenotype was more widespread than initially though.
Multiple receptors triggered elevated responses from B10.RIII NK cells, and NK cells
from poly-I:C-activated B10.RIII mice were more potent at killing target cells than cells
from poly-I:C-activated B10 mice. Moreover, T cells from B10.RIII mice exhibited
elevated IFN! production in response to several stimuli. With such a broad phenotype of
lymphocyte hyperreactivity, it seemed possible that a genetic locus responsible for this
phenotype could also play an important role in autoimmune susceptibility.
An earlier study had gone so far as to implicate a region on chromosome 10 as
being involved in the autoimmune susceptibility of B10.RIII mice (88). We hypothesized
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that the same as-yet unidentified gene in this region might also be the cause of the
hyperreactivity phenotype we observed in NK cell and T cells of the same strain. Since
NK and T cell phenotypes are often more easily measured than severity of autoimmune
disease models, we planned to use T and NK cell stimulation assays to track down the
gene of interest. To test whether the chromosome 10 region carried a gene responsible for
the hyperreactivity phenotype, we created a panel of (B10.RIIIxB6) chimeric mice
carrying the RIII-derived loci at chromosome 10 and/or the MHC locus. However,
experiments performed on these chimeric mice indicated that the RIII-derived
chromosome 10 region of B10.RIII mice does not in fact cause the hyperreactivity
phenotype. Furthermore, the H2r MHC locus, the other documented site of genetic
divergence between B10.RIII mice and the other MHC-congenic strains, also did not
convey hyperreactivity in our panel of (B10.RIIIxB6) chimeric mice. Even 10III H2r
mice, which carry RIII-derived regions at both chromosome 10 and the MHC locus,
failed to reproduce the phenotype of B10.RIII mice.
There are several possible explanations for this finding. First, a genetic locus
outside the known chromosome 10 and MHC regions may be the cause of the
hyperreactivity. Second, the interspersed B6 DNA in these chimeras may somehow affect
the hyperreactivity phenotype. For example, a B6 suppressor locus of some sort may be
counteracting the effect of the B10.RIII hyperreactivity locus. Unfortunately, both of
these possibilities are extremely difficult to evaluate. Third, the causative difference
between the B10.RIII mice and the (B10.RIIIxB6) chimeras may be environmental. The
B10.RIII mice used to date were all purchased from The Jackson Laboratory, whereas the
chimeras were bred in our animal facility. To test whether an undefined environmental
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factor can account for the hyperreactivity of B10.RIII mice, we are breeding B10.RIII
mice in an on-campus animal facility for comparison with genetically identical B10.RIII
purchased from The Jackson Laboratory. These experiments are pending.
The list of environmental factors that can influence lymphocyte activation is long.
The most likely candidates are the intestinal microbiota and occult viral infections. The
physiological effects of the microbiota on the host is a topic that has gained prominence
in recent years. The intestinal microflora has a particularly close and complex
relationship with cells of the immune system. One of the most well-studied links between
the intestinal microbiota and dysregulated immune responses is the role of intestinal
bacteria in inflammatory bowel disease such as Crohn’s disease (112). However, bacteria
in the gut can also affect immune and inflammatory responses at distant sites, such as the
skin (113). Gut microbes have also been shown to affect TH17 population in the gut.
Interestingly, one study found differences in lamina propria TH17 populations between
B6 mice purchased from two different vendors, Taconic Farms and The Jackson
Laboratory (114). The low frequency of TH17 cells in B6 mice from The Jackson
Laboratory was reversed when they were housed for two weeks with mice purchased
from Taconic Farms, and cecal transfer experiments into germ-free mice demonstrated
that intestinal microflora were responsible for the phenotype.
Similarly, occult viral infections could be responsible for the observed differences
in NK and T cell responses to stimulation. Viral infections can cause pro-inflammatory
cytokine environments that prime lymphocytes to respond more robustly to stimulation.
While both the vendor facility and the campus animal facility undergo regular screening
for known pathogens, the possibility of infection by other pathogens, including agents not
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yet isolated and identified, remains. For example, norovirus is prevalent in many animal
facilities yet was only recently identified (115, 116). It is possible that a difference in one
or more occult viral infections between mice bred in vendor labs and our CSRB facility
could play a role in the observed NK and T cell phenotypes.
To make matters even more complicated, it is possible that microbial infections or
the commensal microflora could be acting in conjunction with genetic mutations in the
B10.RIII genome, either in the known RIII-derived regions (i.e., on chromosome 10 and
at the MHC locus) or elsewhere. As a result, the hyperreactivity phenotype may only be
apparent in mice containing both the necessary genetic susceptibility locus (or loci) and a
particular microbe, or set of microbes. The complexity and potentially cooperative nature
of these factors makes identifying the cause(s) of the B10.RIII hyperreactivity phenotype
very difficult, costly, and time-consuming. We have therefore decided not to pursue this
project further.
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Figure 24. B10.RIII NK cells are hyperreactive to activation receptor stimulation.
(A) Splenocytes from MHC-congenic strains B10.RIII (H2r), B10.D2 (H2d) and B10
(H2b) were stimulated with 5 !g plate-bound PK136 (anti-NK1.1), and IFN! production
was assessed by flow cytometry. Shown are mean ± SD of IFN! production frequencies
of Ly49A-monopositive and Ly49/NKG2A-negative NK cells (NK1.1+ CD3- CD19NKG2A- Ly49C- Ly49F- Ly49I-; Ly49G2+ NK cells were also gated out in two of three
experiments) pooled from three independent experiments. N=7 per group. These data are
also displayed in Figure 3B and C. (B) Splenocytes from B10.RIII and B10 mice were
stimulated with antibodies (5 !g) against NK1.1 (PK136), Ly49D (4e5), or Ly49H
(3D10), or with IL-12 and IL-18 (10 and 50 ng/mL final concentration, respectively), or
with PMA/ionomycin. Frequency of IFN! production was then measured by flow
cytometry. Each bar represents one mouse. *: p<0.05; ***: p<0.001.
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A
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Figure 25. Poly-I:C stimulated B10.RIII splenocytes are more efficient at killing
! 2m-/- ConA blast and YAC target cells. One B10.RIII mouse and one B10 mouse were
treated with 300 µg poly-I:C 24 hours before the splenocytes were harvested and used as
effector cells in conventional 51Cr release assays against (A) !2m-/- ConA blast and (B)
YAC target cells. B10.RIII (H2r) ConA blasts were used as MHC-sufficient control cells
in (A).
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Figure 26. B10.RIII hyperreactivity phenotype is cell-intrinsic. Splenocytes from a
B10.RIII mouse and a B10 mouse were simulated with PK136 either separately (107 cells
per well) or together (5 x 106 cells of each type). IFN! production was then assessed by
flow cytometry. B10.RIII and B10 cells were distinguished by H2Kb staining.
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Figure 27. T cells from B10.RIII mice are also hyperreactive to stimulation. B10.RIII
and B10 splenocytes were stimulated with anti-CD3 and -CD28 antibodies, Con A, or
PMA and ionomycin for 8 hours. IFN! production by CD8 T cells (CD8+ CD3+ NK1.1-)
was assessed by intracellular cytokine staining and flow cytometry.

140

B10.RIII
11.4%

10 5

CD3 +
CD28

10 4

10 3

10 3

10 2

10 2

0

0

10

2

10

3

4

10

5

3.5%

10 5

10 3

10 3

10 2

10 2

0

0

10 2

10 3

10 4

10 5

45.4%

10 4

10

10

2

10

3

10

4

10

5

1.3%

10 5

10 4

10 5

CD8

0

10 4

0

PMA/
iono

10

4.4%

10 5

10 4

0

ConA

B10

0

10 2

10 3

10 4

10 5

6.3%

10 5

10 4

3

10

3

10 2

10 2

0

0

0

10 2

IFN!

10 3

10 4

10 5

0

10 2

10 3

10 4

10 5

Figure 28. Microsatellite analysis of B10.RIII confirms the presence of a RIIIderived region on chromosome 10. (A) Microsatellite analysis was performed on tail
DNA from a B10.RIII mouse purchased from Jackson Labs. Each column represents one
microsatellite locus, and bold vertical lines separate the chromosomes. Expected
microsatellite sizes for B6 mice from The Jackson Laboratory and Taconic Farms, B10
mice, and B10.RIII mice are shown for reference. Microsatellite analysis was performed
and figure made by Samantha Taffner of the Rheumatic Diseases Core Center’s Speed
Congenics Lab, Washington University School of Medicine, St. Louis, MO. (B) Diagram
of microsatellite markers used to define the RIII-derived region on chromosome 10.
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Figure 29. (B10.RIIIxB6) chimeric mice do not exhibit hyperreactivity to
stimulation. (A) Four (B10.RIIIxB6) chimeric strains were produced to dissect the roles
of the RIII-derived region on chromosome 10 versus the MHC locus of B10.RIII mice.
The chromosome 10 region refers the region encompassing microsatellite markers
D10mit20 and D10mit178 (see Figure 28B). (B) Normalized frequency of IFN!
production by NK cells (NK1.1+ CD3-) upon stimulation of NK1.1 (5 !g PK136). Data
pooled from three independent experiments. Within each experiment, the data were
normalized to the average frequency of IFN! production by NK cells from 10B6 H2b
mice. (C) Normalized frequency of IFN! production by CD8 T cells (CD3+ NK1.1-) upon
stimulation with PMA/ionomycin. Data pooled from three independent experiments.
Within each experiment, the data were normalized to the average frequency of IFN!
production by T cells from 10B6 H2b mice. *: p<0.05; **: p<0.01; ***: p<0.001.
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Figure 30. Hyperreactivity phenotype of B10.RIII mice is not reproduced by
genetically similar mice bred in a campus animal facility. (A) Normalized frequency
of IFN! production by NK cells (NK1.1+ CD3-) upon stimulation with plate-bound
antibodies against NK1.1 (5 !g PK136) or with PMA/ionomycin. Data pooled from
seven independent experiments. Within each experiment, data were normalized to the
average frequency of IFN! production by B10 or 10B6 H2b control mice. (B) Normalized
frequency of IFN! production by CD8 T cells (CD3+ NK1.1-) upon stimulation with
PMA/ionomycin. Data pooled from seven independent experiments. Within each
experiment, the data were normalized to the average frequency of IFN! production by T
cells by B10 or 10B6 H2b control mice.
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CHAPTER 8

DISCUSSION AND FUTURE DIRECTIONS
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At the outset of the work presented herein, the first formal study of licensing in
mice had only recently been published (27). The discovery of licensing gave rise to a
plethora of questions regarding the determinants of this process. Especially interesting
was how NK cell licensing is affected by the extreme polymorphism of both MHC class I
molecules and the inhibitory NK receptor families (the Ly49 family in mice and KIRs in
humans). With such a staggering number of MHC class I combinations, how does the
affinity of the licensing interaction relate to the licensing phenotype of the NK cell?
Similarly, as MHC class I molecules are co-dominantly expressed, what effect does
expression of one versus two copies of a given MHC class I allele have on NK cell
licensing? Do the two functions of inhibitory NK receptors, i.e., licensing and effector
inhibition, exhibit the same MHC specificities and thresholds? Answers to these
questions would enrich our understanding of the nature of NK cell licensing in
genetically diverse outbred populations.

Licensing of Ly49A+ NK cells in diverse MHC contexts
To investigate NK cell licensing in diverse MHC contexts, we selected a panel of
six MHC-congenic mice on a C57BL/10 background. These MHC-congenic strains carry
the same genomic NKC locus, which encodes the Ly49 family of inhibitory (and
activating) receptors as well as the universally expressed NK cell marker and activation
receptor NK1.1 (90). To determine the effect of different MHC haplotypes on a single
inhibitory NK receptor, we focused on Ly49A+ NK cell subsets in these strains. Ly49A is
a prototypical inhibitory Ly49 receptor whose ability to mediate licensing in mice
expressing H2Dd, a well-known cognate MHC class I ligand, is well established.
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Importantly, the six selected MHC haplotypes have a range of affinities for Ly49A,
representing the diverse affinities of the many possible pairings of MHC class I and
inhibitory NK receptors.
Our studies of licensing of Ly49A+ NK cells in these strains indicate that
licensing is saturated by moderate-affinity MHC class I haplotypes: three of the six
MHC-congenic strains (H2d, H2r, H2k) exhibited similar levels of licensing of Ly49A+
NK cells despite having vastly different affinities for Ly49A. The other three haplotypes
(H2q, H2s, H2b), which exhibited low levels of binding to Ly49A, had Ly49A+ NK cells
with weak licensing phenotypes. Assays of avidity on NK cell licensing in mice with one
versus two gene doses of an MHC class I ligand of Ly49A indicate that licensing via
Ly49A also has a low saturation threshold for Ly49A-MHC class I avidity, even for
moderate-affinity ligands like H2k. Ly49A+ NK cells from mice expressing one gene
dose of a cognate MHC class I ligand were licensed as strongly as Ly49A+ NK cells from
mice expressing twice as much of the same MHC class I molecule. Taken together, these
results indicate that while Ly49A shows specificity for some MHC haplotypes over
others in terms of NK cell licensing, maximal licensing occurs even with haploinsufficient expression of moderate-affinity MHC class I ligands. Thus, while NK cell
licensing is formally analog with respect to MHC class I affinity in that there are multiple
levels of licensing, the low threshold of saturation confers elements of a digital
mechanism as well.
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Effects of a low MHC class I saturation threshold of NK cell licensing
It is tempting to speculate that the low affinity threshold for saturation of NK cell
licensing is an adaptation to the vast polymorphism of MHC class I alleles. For example,
if Ly49 receptors were extremely MHC class I allele-specific and mediated NK cell
licensing (and effector inhibition) only in response to a few of the hundreds of available
MHC class I alleles, Ly49A would have no ligand, and thus no function, in most mice.
Conversely, if Ly49A mediated strong licensing upon interactions with a larger
percentage of MHC class I alleles, Ly49A would play a significant role in many or even
most individual mice. It is easy to conceive that evolutionary pressure would favor the
second scenario, in order to make good use of a given Ly49 receptor. Indeed, in our panel
of MHC haplotypes, Ly49A produced strong licensing in three out of the six strains,
though a more extensive panel of MHC haplotypes is necessary to conclusively test this
hypothesis. The functional binding specificities of other Ly49 receptors would also be
interesting to assess in this context.
On the other hand, why is Ly49A MHC class I allele-specific at all? After all, if
all inhibitory NK receptors bound well to every MHC class I molecule, NK cell licensing
would be easy to achieve for each individual NK cell. The answer to this question may be
found in the ability of NK cells to react to situations analogous to that of “hybrid
resistance.” Hybrid resistance describes the ability of an MHC heterozygous F1 hybrid
mouse to reject bone marrow from either of its MHC homozygous parents (47, 48).
Recipient NK cells are responsible for this BM rejection, and it is dependent on the MHC
environment of the recipient (49, 50).
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While the mechanism of this hybrid resistance long remained a mystery, NK cell
licensing together with the complex MHC class I selectivity and expression pattern of
inhibitory NK receptors provide a compelling, albeit formally unproven, explanation.
Specifically, NK cell licensing predicts that some NK cells are licensed to recognize only
MHC class I molecules inherited from the mother, while others are licensed only by
MHC class I molecules inherited from the father. Yet another NK cell population may
express one or a combination of inhibitory receptors that recognize MHC class I
molecules from both parents and would therefore be licensed by both parental molecules.
Since MHC class I molecules are co-dominantly expressed, each of these three licensed
NK cell subsets can recognize F1 hybrid cells as self. Upon infusion of maternal BM
cells, however, those NK cells that were only licensed by paternal MHC class I molecules
will recognize the BM cells as “missing self” and initiate rejection of these cells.
Similarly, upon exposure to paternal BM, the NK cells solely licensed by maternal MHC
class I molecules may reject the paternal cells. If all inhibitory NK receptors could bind
and induce licensing in response to any MHC class I allele, the ability of NK cells to
reject parental BM would be lost.
Situations analogous to hybrid resistance occur in natural pathological contexts
such as viral infections. For example, MCMV infection of B6 mice causes a drastic
decrease in surface expression of H2Db but only a slight decrease in H2Kb expression
(117). MCMV-infected cells in B6 mice thus effectively lack one but not both self-MHC
class I molecules, mimicking the parental bone marrow of experimental hybrid resistance
models. In this system, NK cells licensed for H2Db but not H2Kb would be best suited to
detect and attack MCMV-infected cells. In sum, expression of MHC class I allele-
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selective inhibitory NK receptors on subsets of NK cells ensures that NK cells can
identify and respond to cells that have down-regulated even just one of the several
expressed MHC class I molecules. In turn, a low affinity/avidity-threshold for licensing
permits many combinations of inhibitory NK receptor and MHC class I molecules to
perform this function.

Weakly licensed NK cells: possible physiological relevance
In our licensing studies of MHC-congenic mice, the MHC haplotypes that did not
produce saturated licensing of Ly49A+ NK cells, i.e. H2q, H2s, and H2b, nonetheless
produced weak licensing of these cells. Ly49A+ NK cells from mice of these MHC
haplotypes produced IFN! at a lower frequency than Ly49A+ NK cells of the H2d, H2r,
and H2k haplotypes, which produced saturated licensing, but at a higher frequency than
Ly49A+ NK cells from MHC class I-deficient cells. However, it is unclear whether this
weak level of licensing is functionally relevant in vivo. After all, while these MHC
haplotypes do exhibit statistically significant binding of soluble Ly49A tetramers, the
level of binding is very low, especially for H2b and H2s. The weak licensing of Ly49A+
NK cells in these mice may be the result of essentially non-specific interactions of Ly49A
with MHC class I, interactions that do not occur in Kb-/- Db-/- mice but that occur in all
MHC class I-expressing mice. Further studies are needed to explore this issue.
In the meantime, a study looking at bone marrow rejection by three MHC class Itransgenic may suggest that weakly licensed NK cells can in fact play a role in missing
self detection (118). Johansson et al found that expression of H2Ld alone can license NK
cells to reject "2m-/- BM, but NK cells from mice that express H2Ld along with H2Kb and
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H2Db are unable to detect missing H2Ld (e.g., on H2KbDb BM). The authors suggest that
H2Ld weakly licenses NK cells. However, this study did not define the NK cell subsets
responsible for bone marrow rejection in each case, making it difficult to distinguish the
contributions of particular NK cell subsets. Also, the inability to detect missing H2Ld
when stronger licensing interactions are present suggests that strong licensing stimuli
override weak licensing signals, thus eliminating any real benefit of weak licensing in
most MHC contexts. Moreover, there are other possible interpretations of the data in this
study. For example, H2Ld may bind the same inhibitory NK receptor as H2Kb or H2Db. If
so, the BM that lacks H2Ld but expresses H2Kb and H2Db would not be identified as
“missing self” because the H2Ld-binding inhibitory NK receptor would recognize H2Kb
or H2Db as self-MHC. In sum, it remains possible that weak licensing of NK cell subsets
may be physiologically relevant, but more studies are needed.
MHC-congenic mice could be useful tools for these further studies of weak
licensing. For example, in mice heterozygous for the H2b and H2q MHC haplotypes,
Ly49C-monopositive NK cells will be strongly licensed (by H2Kb), while Ly49Amonopositive NK cells will be weakly licensed. What is the phenotype of NK cells that
express both Ly49C and Ly49A? Will the licensing phenotype of these cells differ from
Ly49C-monopositive NK cells? In other words, does the potential weak licensing
conferred by Ly49A add to the potency of the double-positive subset, or does it fail to
make a mark on the face of strong licensing via Ly49C? Recent studies have assessed the
potency of NK cell subsets expressing different numbers of self-specific inhibitory NK
receptors (75, 76). They found that NK cell potency increased with increasing numbers of
self-MHC class I-specific Ly49 receptors. However, these studies lacked binding assay
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data for the relevant Ly49 and NKG2A/CD94 receptors and MHC class I contexts. Thus,
it would be informative to revisit this issue in a more controlled environment such as the
system described above.

Cis and trans engagement of Ly49 receptors in NK cell licensing
Ly49 receptors can engage MHC class I molecules in cis and in trans.
Interestingly, the extent of cis engagements of Ly49A with the six MHC haplotypes
correlated better with NK cell licensing than did the strength of trans engagement of
Ly49A with MHC class I. Most notably, the saturation threshold for licensing coincided
with that of saturation of cis engagement. These findings represents evidence, albeit
circumstantial, that cis interactions of Ly49A with MHC class I determine licensing. This
conclusion is consistent with a recent study by Werner Held and colleagues, who used an
engineered Ly49A molecule incapable of engaging MHC class I in cis to demonstrate
that cis interactions of MHC class I with Ly49A are required for licensing (73). Held and
colleagues also propose a mechanism for this observation and, by extension, NK cell
licensing in general. They suggest that unengaged Ly49A produces a tonic inhibitory
signal that is terminated upon cis engagement of Ly49A with MHC class I. In MHC class
I-deficient mice, all inhibitory NK receptors lack ligands, and the tonic inhibitory signals
emitted by these unengaged receptors dampens the cells’ responses to stimuli, thereby
producing an unlicensed phenotype. In wild-type mice, some NK cells express Ly49
receptors that can engage self-MHC in cis and thus stop tonic inhibitory signaling from
those Ly49 receptors. These NK cells are consequently more responsive to stimulation
and exhibit a licensed phenotype.
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However, while this mechanism is consistent with much of the current available
data, it fails to explain the behavior of NK cells in mice with mosaic MHC class I
expression. For example, in mice with constitutive mosaic expression of H2Dd, Ly49A+
NK cells that express H2Dd, a cognate ligand of Ly49A, do not exhibit a licensed
phenotype (63). Similarly, in an example drawn from work presented herein, induction of
mosaic expression of a Kb-ova SCT molecule on NK cells does not produce licensed
Ly49C+ NK cells. If cis engagement of MHC class I by an inhibitory NK receptor were
both necessary and sufficient for licensing, mosaic expression of a MHC class I molecule
should license NK cells that express both the MHC class I molecule and its cognate
inhibitory NK receptor. In reality, the entire NK cell population, regardless of MHC class
I expression, is unlicensed. These data indicate that the cis binding mechanism of NK cell
licensing does not represent the entire story. More experiments are needed to address this
issue.
A curious point regarding the relationship of licensing and cis engagement of
inhibitory NK receptors is that KIRs, which are functionally analogous to Ly49 receptors,
are not thought to engage HLA molecules in cis. If cis engagement is indeed required for
licensing via inhibitory Ly49 receptors as recent data indicates (73), how do KIRs
mediate licensing without cis engagement? A recent study may provide some clues
regarding why KIRs do not engage HLA molecules in cis (68). Back et al find that trans
engagement of Ly49 with MHC class I enhances adhesion between the two interacting
cells, whereas KIR-HLA binding does not enhance adhesion (119-121). The authors
propose that the purpose of cis interactions of Ly49 receptors is to reduce receptor
availability in order to prevent NK cells from attaching too tightly to normal cells since
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this could impede efficient NK cell surveillance of normal tissues (68). Since KIRs do
not affect adhesion, they do not require HLA blockade in cis for optimal NK cell
function. This theory implies that the purpose (or at least one purpose) of receptor
calibration is to modulate adhesion in favor of interactions with missing-self cells, not to
maintain self-tolerance per se. Clearly, more work needs to be done in order to fully
understand the role of cis interactions in NK cell licensing.

NK cell licensing and effector inhibition have different MHC class I affinity thresholds
Inhibitory NK receptors have two functions: licensing and effector inhibition.
Both of these functions require MHC engagement and the ITIM of the inhibitory NK
receptor. However, whether the MHC specificities and affinity thresholds are the same
for licensing and effector function has not previously been assessed. Experiments
addressing the ability of MHC-congenic target cells to inhibit killing by Ly49A+ LAK
effector cells indicate that effector inhibition is more sensitive to MHC class I
engagement than is NK cell licensing. In other words, MHC haplotypes that produce
poorly licensed Ly49A+ NK cells, such as H2q and H2s, are still able to inhibit Ly49A+
LAK cytotoxicity relatively well. In particular, target cells of the H2q haplotype were
almost as effective as H2k target cells at inhibiting Ly49A+ effector cell cytotoxicity,
despite being much less potent at licensing Ly49A+ NK cells.
The apparent differences in activation thresholds of NK cell licensing and effector
function are reminiscent of T cell tolerance, in which the signal threshold for negative
selection in the thymus is lower than for activation in the periphery (122-125). For
example, low-avidity peptide:MHC class I complexes that induced deletion of developing
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thymocytes were unable to stimulate mature effector T cells (124). In this way, all T cells
that have any chance of reacting to self-antigens in the periphery are deleted. A similar
safeguard may govern the licensing of NK cells such that only NK cells capable of
achieving a strong interaction with self-MHC become licensed. A more sensitive
threshold of inhibition in the periphery ensures that licensed NK cells are strongly
inhibited by self-MHC class I and thus maintain tolerance to healthy self cells.

ITIM-mediated signaling of NK cell licensing and effector function
The difference in threshold of NK cell licensing and effector inhibition may
reflect differences in the signaling cascades that mediate these events. While Ly49Amediated effector inhibition relies mainly upon signaling initiated by SHP-1, the precise
signaling pathways required for licensing remain unclear (14, 98, 99). SHP-1 does not
appear to be required for licensing, though a role for SHP-1 cannot be formally excluded
because these experiments used a hypomorphic mutant of SHP-1 (me-v) (27). In addition,
SHP-1-deficient (me) mice have pleiotropic effects including profound inflammation that
may affect the MHC-dependent licensing status of NK cells (126).
There are at least 3 other intracellular molecules that have been reported to bind to
ITIMs, including SHP-2, SHIP, and p85# of PI-3K (127-129). SHP-2 knockout mice
have not been examined in licensing because they are embryonic lethal before
hematopoiesis occurs (130). Preliminary studies of knockout mice by our group suggest
that neither SHIP nor p85# of PI-3K is involved in licensing (27). Other published
studies found that SHIP-/- NK cells do or do not reject "2m-/- BM depending on the
genetic background of the knockout mouse (67, 131). Thus, it has been challenging to
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further decipher the role of the ITIM in licensing by using mice deficient in molecules
known to bind the ITIM.
Another point to consider about the role of ITIM in licensing is that its function
has been historically defined in terms of effector inhibition. However, it is possible that
the ITIM may exert a “positive” effect on cellular processes. Notably, a recent study
indicates that SHP-1 can lead to net positive functions of an immune cell: SHP-1
increases type I IFN production and decreases pro-inflammatory cytokine secretion in
dendritic cells in response to Toll-like receptor (TLR)-3 or -4 stimulation (132).
Curiously, the phosphatase domain of SHP-1 does not seem to be necessary for this
effect. Another recent study found that signaling through an inhibitory KIR led to
phosphorylation of the adaptor protein Crk (53). The ability of an inhibitory receptor to
cause phosphorylation of a downstream signaling molecules suggests that ITIMdependent signaling is much more diverse than previously thought. Together, these
findings indicate that categorizing receptors and signaling molecules as “inhibitory” or
“activating” may not reflect the true complexity of their biology.
Regardless, the use of different signaling mechanisms does not fully address the
question of how an NK cell distinguishes licensing interactions from inhibitory stimuli
during effector responses. This is a particularly important question in light of our findings
that NK cell licensing does not need to occur during development. If mature, peripheral
NK cells can undergo licensing, there is no environmental or temporal context to
distinguish licensing from effector inhibition. Furthermore, as cis interactions are not
sufficient for NK cell licensing, a structural explanation of signaling for licensing versus
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effector inhibition also seems unlikely. The regulatory mechanisms of NK cell licensing
and inhibition clearly warrant further study.

MHC class I engagement thresholds of licensed versus unlicensed NK cells
It is currently unclear whether the MHC class I affinity and avidity thresholds for
effector inhibition differ between licensed and unlicensed NK cells. Previous work has
demonstrated that licensed cells are less prone to inhibition by their cognate MHC class I
ligand because of reduced inhibitory receptor availability (the basis of the “receptor
calibration” model of NK cell tolerance), resulting from a blockade of the inhibitory
receptor by cis engagements with MHC class I (43). Is the observed difference in
reactivity solely due to receptor accessibility, or is there also an internal difference in
threshold between licensed and unlicensed NK cells? Does NK cell licensing through
one Ly49 receptor alter the responsiveness of an NK cells to effector inhibition signaled
by a different Ly49 receptor? Studies to address these questions are now possible with
the availability of diverse MHC-congenic and-transgenic strains and a thorough
understanding of the licensing and effector inhibition phenotypes of Ly49A and Ly49C
receptors.
Interestingly, a recent study has suggested that unlicensed cells are the most
effective population at fighting MCMV infections (51). Orr et al used antibodies to
deplete Ly49C/I+ NK cells, which are licensed by H2Kb, before infecting B6 mice with
MCMV. They found that depleting these licensed NK cell subsets had no impact on
survival of viral titers, whereas partial depletion of unlicensed NK cells caused elevated
viral titers and decreased survival. Inhibitory interactions between H2Kb and Ly49C or
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Ly49I prevented Ly49C/I+ NK cells from proliferating and mounting an effective
response to MCMV-infected cells. In comparison, unlicensed cells, which by definition
cannot be inhibited by engagement of self-MHC, were more protective. However, given
that H2Kb surface expression is only slightly reduced on MCMV-infected cells (117), this
is not a surprising finding. NK cell licensing produces cells that are potent responders to
“missing self,” which means activation stimulus in the absence of MHC class I
engagement. The self-tolerance of these cells is maintained through inhibition by selfMHC class I. These MHC class I-dependent inhibitory pathways are intact even in the
presence of a general inflammatory environment such as during a viral infection. A more
rigorous test of the role of licensed versus unlicensed cells in the early immune response
to viral infection would compare responses of licensed NK cells whose cognate MHC
class I ligand is actually down-regulated by the infection. This could be done by
assessing the contribution of Ly49A+ NK cells to the antiviral response to MCMV
infection in B10.D2 mice, which express MHC class I molecules of the H2d haplotype
that are highly susceptible to down-regulation by MCMV (117).

Establishing a model of inducible NK cell licensing
While important information has been gained from the study of static licensed NK
cell populations, we may learn even more by studying the events of licensing as they
occur. An inducible model of licensing would provide access to synchronized NK cell
populations undergoing the as-yet unidentified molecular events of this process. The
synchronicity of the cells would improve our ability to detect the changes, especially
transient changes, that occur during the process of NK cell licensing. An inducible
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system would also allow us to identify what factors, cells, and time spans are necessary
for producing licensed NK cells. By applying the system to mice that lack candidate
signaling molecules or other components, inducible licensing would permit tests of the
requirement of these components in NK cell licensing with better controls for
developmental or pleiotropic effects than previous studies.
A system of peptide stabilization of H2Kb molecules in TAP1-deficient mice was
not robust enough to produce licensed NK cells. Peptide administration into TAP1deficient mice produced H2Kb stabilization at a barely detectible level, which clearly did
not reach the threshold necessary for NK cell licensing. We next produced a Tet-On
system of MHC class I expression, in which doxycycline treatment induces expression of
a Kb-ova single-chain trimer (SCT). The first iteration of this model paired the SCT
transgene with a rtTA Tet-On transactivator transgene with an H2Kb promoter and IgH
enhancer element. However, the SCT tg rtTA tg mice exhibited mosaic expression of the
Kb-ova SCT molecule. Expression of Kb-ova on a minority of cells did not produce
licensed NK cells, consistent with published studies of mice with mosaic expression of
MHC class I molecules (60, 63).
A second iteration of the Tet-On system of Kb-ova SCT expression uses a rtTA
gene knocked into the Rosa locus. These mice have been used to drive expression of
transgenes with a broad tissue expression profile, including spleen, thymus, and bone
marrow (108). While this model is not yet ready for assays of NK cell licensing, Kb-ova
expression studies are very promising. Upon doxycycline treatment, nearly all
splenocytes express Kb-ova. This unimodal, near-universal expression of Kb-ova should
be sufficient for NK cell licensing. Current plans are to breed these mice to a "2m-/-
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background in order to establish a baseline state of unlicensed NK cells in the absence of
doxycycline. When doxycycline is administered, Kb-ova will be expressed as the sole
MHC class I molecule.
It will be important to establish the doxycycline dose-response curve of Kb-ova
expression in these mice. Such studies would reveal the minimum doxycycline dose
necessary for maximal Kb-ova expression, reducing the risk of potential doxycyclinerelated side effects in future studies. In addition, these studies may also establish a doseresponse curve for producing different levels of Kb-ova expression. Using different doses
of doxycycline to manipulate Kb-ova expression levels may allow us to identify the
minimum threshold of MHC class I necessary for NK cell licensing.
After these optimization experiments, we can pursue studies of NK cell licensing
upon induction of Kb-ova expression both in vivo and in vitro. Licensing of NK cells
upon Kb-ova expression in vivo would not only be a proof of principle of our system. It
would also suggest that NK cell licensing is plastic. The plasticity of NK cell licensing
has recently been demonstrated through the use of adoptive transfer experiments in which
MHC class I-deficient cells appear to become licensed upon transfer into wild-type hosts
(Julie Elliott and WMY, manuscript in preparation). However, the adoptive transfer
model is limited to the study of very small numbers of cells that have undergone
necessary ex vivo manipulations during the course of the adoptive transfer. The Tet-On
model of inducible licensing does not require isolation or other direct manipulation of
cells. In addition, the Tet-On system of Kb-ova expression will induce licensing of the
entire Ly49C+ NK cell subset, a much larger population of cells than the small number of
Ly49C+ NK cells available under the adoptive transfer protocol. These larger populations
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are more conducive to assays such as viral infection survival studies to test the function
of these inducibly licensed cells, and they also enable isolation of enough cells for study
using Western blots and other techniques that require large cell numbers.
Experiments of inducible licensing in vivo could include a time course comparing
the timing of Kb-ova expression with the emergence of licensed Ly49C+ NK cells. Future
studies may also include bone marrow chimeras to compare the relative contributions of
hematopoietic and non-hematopoietic cell lineages to NK cell licensing. Interpretation of
previously published studies of MHC class I-disparate bone marrow chimeras is
complicated by the fact the lethal irradiation causes an inflammatory environment that
may affect NK cell licensing. By inducing Kb-ova expression several weeks after the
irradiation and bone marrow transplant, NK cell licensing can be investigated after the
irradiation-associated inflammation has subsided.

Transfer of specific MHC class I molecules in MHC class I-chimeric contexts
One issue that affects interpretation of studies like the mixed bone marrow
chimeras is the possibility of MHC class I transfer to NK cells. Inhibitory Ly49 receptors
can transfer (steal) MHC class I molecules from other cells onto their own cell membrane
(94, 95). In fact, receptor transfer by trogocytosis is a relatively common occurrence for
immune cells (133). Ly49-mediated transfer happens within 20 minutes and occurs only
for specific MHC ligands of the inhibitory receptor. Expression of cognate self-MHC
ligands on the NK cell in cis blocks MHC class I transfer by Ly49 receptors on that cell
(95). Levels of MHC class I can reach as high as 30% of levels found on the donor cells
and leads to a concomitant reduction in accessible surface Ly49, implying that the Ly49
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receptor then becomes engaged in cis (94, 95). Notably, culture in IL-2 overnight led to a
loss of acquired MHC class I molecules (94). The functional outcomes of MHC class I
transfer with regard to licensing are not clearly understood, but this phenomenon may be
relevant to other experiments where such transfer may have occurred. For example, a rat
NK cell line transfected with Ly49A and pre-incubated with a H2Dd-expressing cell line
(to allow transfer of H2Dd) showed reduced killing of a NK susceptible cell line,
indicating that MHC class I transfer may indeed have functional consequences (94).
These issues must be taken into account in any experiment involving MHC-chimeric or
mosaic animals.

Non-genetic factors may affect NK cell phenotypes
One project of this dissertation followed an unpredictable course that represents a
reminder to exercise caution when interpreting any phenotype thought to be due to
genetic differences. In our early NK cell licensing studies in MHC-congenic mice,
B10.RIII (H2r) mice produced unusually robust IFN! responses to stimulation through
the NK1.1 activation receptor. Further bench and literature research led to the hypothesis
that the B10.RIII strain exhibits a generalized lymphocyte hyperreactivity that may be
caused by a locus in the RIII-derived region of genetic contamination on chromosome 10.
This region has been linked to the susceptibility of the B10.RIII strain to collageninduced arthritis and perhaps also other models of autoimmune disease (88, 111).
(B10.RIIIxB6) chimeric mice were produced in order to compare the contributions of the
H2r MHC locus and the RIII-derived region on chromosome 10 to the hyperreactivity of
NK cells and T cells. Surprisingly, even mice that carried B10.RIII-derived loci at both
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these regions did not exhibit the hyperreactivity phenotype observed in B10.RIII mice.
We currently suspect that the B10.RIII phenotype may be due to an environmental factor,
such as the commensal microbiota, as B10.RIII mice were purchased from a vendor
whereas the (B10.RIIIxB6) chimeric mice were bred in an on-campus animal facility. We
are currently breeding B10.RIII mice in the on-campus animal facility for experiments to
compare lymphocyte phenotypes in vendor-born versus locally born B10.RIII mice.
The B10.RIII hyperreactivity project demonstrates the importance of ruling out
environmental factors in studies where the origins of the mice differ. In many
experiments involving genetically engineered mice, the genetically modified mouse is
bred in an on-campus animal facility whereas the control mice are purchased from a
vendor. Any number of small differences in the physical environments provided by the
vendor facility and the local animal facility may affect the phenotype of a mouse,
differences that may be erroneously attributed to the genetic locus being studied. These
issues must be kept in mind and should ideally be addressed in every study that includes
mice with different origins. Controlling for environmental factors is similar to the habit
adopted by many labs of verifying the genetic purity of newly received strains using
microsatellite or single-nucleotide polymorphism (SNP) analysis. These precautions may
seem excessive, but they can ultimately save time and invariably produce a greater degree
of confidence in the findings.

NK cell licensing in human health and disease
A growing number of human studies have demonstrated a link between specific
inhibitory KIR-HLA ligand pairs and protection against progression or poor outcome of
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disease. For example, individuals who carry a certain inhibitory KIR with its cognate
HLA ligand have improved resolution of hepatitis C, slower progression to AIDS, and
reduced risk of human papillomavirus-associated cervical cancer (81, 91, 93). At first
glance, these studies appeared counterintuitive when considered only in the context of the
effect of inhibitory receptors and ligands in the effector response, as an inhibitory NK
cell receptor–ligand interaction would be expected to reduce NK cell activity and thereby
impede the immune response. However, NK cell licensing provides a strong explanation
for these clinical observations, as the licensing interaction of an inhibitory NK cell
receptor with its cognate MHC ligand produces a more potent NK cell in both mice and
humans (27, 80).
Moving beyond these epidemiological studies to direct and detailed studies of
human NK cell licensing has proven difficult. Both HLA genes and KIR genes are highly
polymorphic, and binding studies of each possible combination of HLA and KIR alleles
are not feasible. Studies of NK cell function to date have approached this problem of
HLA and KIR diversity in a binary fashion by sorting KIR and HLA alleles into groups
of “ligands” and “not ligands.” These studies have been greatly informative considering
their genetic limitations and assumptions. However, the tremendous diversity of
inhibitory KIR-HLA combinations is central to NK cell function, as demonstrated by the
complex MHC specificities and expression patterns of inhibitory KIRs. As such, the
effect of different KIR-HLA ligand pair affinities on NK cell licensing and function
deserves study but cannot be addressed by binary studies. A more complete
understanding of NK cell function in humans will require a more subtle approach that
takes into account the biochemistry of each individual inhibitory KIR-HLA pair.
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The work described in this dissertation provides a foundation for these future
studies by exploring the licensing impact of a given murine inhibitory NK receptor
(Ly49A) in diverse MHC contexts and in MHC haploinsufficient settings. The finding of
a low MHC class I saturation threshold for NK cell licensing indicates that inhibitory NK
receptors can mediate strong licensing in response to MHC class I ligands with a wide
range of binding affinities. As a possible safeguard against NK cell autoreactivity, the
MHC engagement threshold of effector inhibition was even lower than for NK cell
licensing. These low saturation thresholds may reflect an evolutionary adaptation to the
high degree of polymorphism of both MHC and Ly49 genes. Whether these
characteristics also hold true for KIR-mediated licensing and effector inhibition of human
NK cells is not known. The murine studies described herein provide a framework of
hypotheses regarding human NK cell function that can be directly and efficiently tested
to improve our understanding of NK cells in human health and disease.
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